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Abstract 
Osteoarthritis (OA) is the main reason for lameness in racehorses. OA is 
currently clinically diagnosed late in the disease process, when irreversible 
damages to the articular cartilage have become evident. Diagnostic biomarkers 
that can detect the disease before irreversible tissue damage and prior to the 
onset of clinical signs would be very desirable. These biomarkers could be 
used to monitor the progression of articular cartilage destruction, repair, and 
inflammatory status. In order to develop biomarkers, it is necessary to further 
elucidate the pathogenesis of OA. The initiation and development of OA 
involves inflammatory processes mediated by pro-inflammatory cytokines. The 
objective of this thesis was to investigate the influence of cytokines, known to 
be involved in OA development, on equine articular chondrocytes in vitro. The 
aim was to increase the knowledge of the complex molecular mechanisms of 
the extracellular matrix (ECM), which may be responsible for the 
development, and progression of OA.  
Healthy equine articular cartilage was stimulated with cytokines 
(interleukin (IL)-1β, HMGB-1, and IL-6) in two in vitro models (explants and 
three-dimensional pellet cultures). Analyses were performed by: 
immunohistochemistry, immunoassays (ELISAs, Western blot), biochemical 
assays (glycosaminoglycan content), quantification of gene expression, and 
quantitative proteomics. Additionally, synovial fluid collected from horses 
with healthy or OA joints was analysed with regard to content and 
glycosylation profile of lubricin. 
Our studies showed that IL-1β induced a catabolic response in ECM-related 
genes and proteins. A time-dependent release of ECM proteins from equine 
explants was also detected. HMGB-1 stimulation of chondrocyte pellets 
indicated a promotion of chondrocyte differentiation or increased metabolic 
activity of chondrocytes. IL-6 stimulation of chondrocyte pellets inhibited the 
canonical Wnt-signalling pathway and upregulated the gene expression of 
growth differentiation factor (GDF)-5. The O-glycosylation profile of lubricin 
in synovial fluid was different for equine joints with OA compared to the 
 normal joints/controls. Additionally, an endogenous cleavage site of lubricin 
was found both in vitro and in vivo. 
The results from this thesis confirm IL-1β as a master cytokine in equine 
articular cartilage destruction. Furthermore the results indicate that IL-6 has a 
regulatory or protective role on articular cartilage metabolism. The results from 
the in vitro studies of equine articular cartilage render novel findings regarding 
the detailed and time-dependent ECM protein release caused by cytokines 
involved in OA. This knowledge can be used for the development of diagnostic 
biomarkers of early OA in vivo. 
Keywords: articular chondrocytes, in vitro, cytokines, osteoarthritis, horse, IL-1β, IL-6, 
inflammation, extra cellular cartilage matrix  
Author’s address: Emilia Svala, SLU, Department of Biomedical Sciences and 
Veterinary Public Health, P.O. Box 7028, 750 07 Uppsala, Sweden  
E-mail: Emilia.Svala@slu.se
 Dedication 
In loving memory of my grandmother Linnéa. 
 
Nog finns det mål och mening i vår färd -  
men det är vägen, som är mödan värd. 
Karin Boye 
  
 Contents  
List of Publications 9	  
Abbreviations 12	  
1	   Introduction 14	  
1.1	   General background 14	  
1.2	   Articular cartilage 15	  
1.2.1	   Molecular organization of articular cartilage 17	  
Collagens 18	  
Proteoglycans 19	  
Non-collagenous matrix proteins 20	  
1.3	   Joint structure changes in osteoarthritis 23	  
1.3.1	   Osteochondral fragments 26	  
1.4	   Factors involved in the development of OA 26	  
1.5	   Inflammation 27	  
1.5.1	   Interleukin-1β and Tumor necrosis factor-α 28	  
1.5.2	   Interleukin-6 29	  
1.5.3	   High-mobility group box protein-1 (HMGB-1) 29	  
2	   Aims of the thesis 31	  
3	   Hypotheses 33	  
4	   Material and methods 34	  
4.1	   Animals and sample collection (papers I-IV) 34	  
4.2	   Isolation and expansion of chondrocytes (papers I-II) 34	  
4.3	   In vitro chondrocyte culture models (papers I,II,III,IV) 35	  
4.3.1	   Three-dimensional chondrocyte pellet cultures (papers I-II) 35	  
4.3.2	   Explant cultures (paper III-IV) 36	  
4.3.3	   Cytokine stimulation (paper I-IV) 36	  
4.4	   Histological methods (papers I,II,III) 37	  
4.4.1	   Fixation 37	  
4.4.2	   Histological stainings (papers I,II,III) 37	  
4.4.3	   Immunohistochemical stainings (paper I-II) 37	  
4.5	   Gene expression analyses 38	  
4.5.1	   RNA isolation and quantification (papers I,II) 38	  
4.5.2	   Complementary DNA synthesis 38	  
4.5.3	   Quantitative real time polymerase chain reaction (qRT-PCR) 38	  
qRT-PCR protocol 39	  
Primers and probes 39	  
4.5.4	   Microarray (paper II) 40	  
 4.6	   Biochemical analyses (paper III) 41	  
4.6.1	   Measurement of glycosaminoglycans. 41	  
4.7	   Protein expression analyses (papers III-IV) 41	  
4.7.1	   Proteomic analyses 41	  
Sample preparation 43	  
Labelling of culture media with isobaric mass tags 43	  
Liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis
 43	  
Database search and TMT quantification 43	  
Characterization of endogenous proteolytic peptides of lubricin in synovial 
fluid 44	  
4.7.2	   Western Blot 44	  
COMP 44	  
Lubricin 45	  
4.7.3	   ELISAs 45	  
Chondroitin sulphate 846 (CS846) 45	  
MMP-13 45	  
C1, 2C 45	  
Lubricin 46	  
4.8	   Glycomic analysis 46	  
4.9	   Statistics 46	  
5	   Results 48	  
5.1	   Paper I 48	  
5.2	   Paper II 49	  
5.3	   Paper III 51	  
5.4	   Paper IV 53	  
6	   General discussion 57	  
6.1	   In vitro methods: chondrocyte pellets and cartilage explants 57	  
6.2	   Effects of the cytokines IL-1β, IL-6 and HMHB-1 on chondrocyte pellets in 
vitro (papers I and II) 58	  
6.3	   Effects of IL-1β stimulation on the secretome of articular cartilage 
explants cultured in vitro (paper III) 61	  
6.4	   Presence of GDF-5 in normal articular cartilage and OCFs (paper II) 63	  
6.5	   Characterization of lubricin (paper IV) 63	  
6.6	   Horse as a model system for translational OA research 65	  
6.7	   Change in diagnostic procedure of osteoarthritis 66	  
7	   Conclusions 67	  
8	   Future research 68	  




List of Publications 
This thesis is based on the work contained in the following papers, referred to 
by Roman numerals in the text: 
I Ley, C., Svala, E., Nilton, A., Lindahl, A., Eloranta, ML., Ekman, S. and 
Skiöldebrand, E. (2011). Effects of high mobility group box protein-1, 
interleukin-1β, and interleukin-6 on cartilage matrix metabolism in three-
dimensional equine chondrocyte cultures. Connective Tissue Research 
52(4), 290-300. 
II Svala, E., Thorfve, A., Ley, C., Henriksson, HB., Synnergren, J., Lindahl, 
A., Ekman, S. and Skiöldebrand, E. (2014). Effects of interleukin-6 and 
interleukin-1β on expression of growth differentiation factor-5 and Wnt 
signaling pathway genes in equine chondrocytes. American Journal of 
Veterinary Research 75(2), 132-140. 
III Svala, E., Löfgren, M., Sihlbom, C., Rüetschi, U., Lindahl, A., Ekman, S. 
and Skiöldebrand, E. (2014). An inflammatory equine model demonstrates 
dynamic changes of immune response and cartilage matrix molecule 
degradation in vitro. (Submitted) 
IV Svala, E*., Jin, C*., Rüetschi, U., Ekman, S., Lindahl, A., Karlsson, N., 
and Skiöldebrand, E. (2014). Characterization of lubricin in synovial fluid 
from horses with osteoarthritis. (In manuscript)  
Papers I-II are kindly reproduced with the permission of the publishers.  




The contribution of ES to the papers included in this thesis was as follows: 
I Second author. Active part in the planning and design of the study. 
Performed the in vitro chondrocyte pellet culture, gene expression analysis 
and immunoassays. Active in presenting data from these experiments, and 
active in the drafting and revising the manuscript. 
II Main author. Active part in the formation of hypothesis and study design. 
Major responsibility for the planning and organization of the study. 
Performed the majority of the experiments and analyses, such as in vitro 
cultures, gene expression analyses and immunohistochemistry. Interpreted 
and summarized the microarray data. Performed the presentation of the 
data and statistical analyses. Drafted and edited the manuscript. 
III Main author. Active part in the formation of hypothesis and study design. 
Major responsibility for the planning and organization of the study. 
Performed all experiments (in vitro cultures, immunoassays, biochemical 
analysis, Western Blot) except the mass spectrometry analyses. Interpreted 
and summarized the mass spectrometry data. Performed the presentation of 
the data and drafted/edited the manuscript. 
IV Main author. Active part in the planning and design of the study, together 
with the second author. Performed the in vitro cultures. Interpreted and 
summarized the results. Active in presenting the data from these 






3D three dimensional 
ADAMTs a disintegrin and metalloproteinase with thrombospondin motifs 
AgPAGE agarose polyacrylamide composite gel  
BSA bovine serum albumin 
C1, 2C carboxy terminus neoepitope of the ¾ piece of collagen type I 
and II 
C3 third carpal bone  
cDNA complementary DNA 
COMP cartilage oligomeric matrix protein 
CS846 chondroitin sulphate 846 
DAPI 4',6-diamidino-2-phenylindole dihydrochloride 
DMEM/F12 Dulbecco’s modified eagle medium: nutrient mixture F-12  
DRF dorsal radial facet 
ECM extra cellular matrix 




GDF-5 growth differentiation factor-5 
GlcNAc N-acetylglucosamine 
GUSB beta glucoronidase 
HMGB-1 high mobility group box protein -1 
HRP horseradish peroxidase  
IL interleukin 
LC/MS-MS liquid chromatography-tandem mass spectrometry 




mRNA messenger ribonucleic acid 
NC4 N-terminal non-collagenous domain 
Neu5Ac N-acetylneuraminic acid 
Neu5Gc N-glycolylneuraminic acid 
OA osteoarthritis 
OCF osteochondral fragment 
PAGE polyacrylamide gel electrophoresis 
PBS phosphate buffered saline 
PC palmar condyle 
PEST pencillin-streptomysin 
PVDF polyvinylidene fluoride  
qRT-PCR quantitative real time polymerase chain reaction  
RA rheumatoid arthritis 
SDS sodium dodecyl sulphate 
SLRPs small leucine rich proteins/proteoglycans 
SOX-9 sex determing region on the Y chromosome–related  
high mobility group box-9 
TGF-β transforming growth factor beta 
TMT tandem mass tag 
TNF-α tumor necrosis factor –α 
 14 
1 Introduction 
1.1 General background 
 
Osteoarthritis (OA) is a highly prevalent, chronic, and disabling disease 
(Johnson & Hunter, 2014) leading not only to articular cartilage destruction but 
also involving the entire joint and its structures: articular cartilage, subchondral 
bone, synovial membrane/capsule, and ligaments (Lane et al., 2011). The full 
pathogenesis for OA is unknown but factors suggested to contribute to the 
development of the disease are joint injury, mechanical loading, age, obesity, 
and genetics (Johnson & Hunter, 2014). Inflammation is always involved 
(Sokolove & Lepus, 2013; Goldring & Goldring, 2007; Saxne et al., 2003; 
Pelletier et al., 2001). 
It is estimated that 12% of the adult human population aged ≥ 18 years have 
symptomatic OA (Hunter et al., 2014b) and its prevalence increases with age 
to encompass nearly 34% of those over 65 (Neogi, 2013). The joint most often 
affected by OA in humans is the knee, and the lifetime risk of developing the 
disease in this joint is as high as 45% (Neogi, 2013). Considering how many 
patients that never seek medical advice, the number is probably much higher. 
The individual burdens, to name a few, include pain, stiffness, and activity 
limitation leading to a lower quality of life. The socioeconomic cost that 
follows is tremendously high (Hunter et al., 2014b). Currently there is no 
disease-modifying drug for structural progression of OA (Jotanovic et al., 
2014) and therefore the available treatments aim to relieve pain. 
In horses, OA is a main reason for lameness (McIlwraith et al., 2012). The 
disease can develop at a young age in racehorses and is also a naturally 
occurring disease in older horses (McIlwraith et al., 2012; Bjornsdottir et al., 
2004). The metacarpophalangeal (MCP) (Neundorf et al., 2010), followed by 
the carpal, are the most commonly OA-afflicted joints in horses (McIlwraith et 
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al., 2012). Racehorses develop OA at a young age due to the heavy and 
repetitive mechanical load from high-speed training and racing (Poole, 1996). 
Horseracing is a multibillion industry in Sweden and the economic importance 
of the horse sector is enormous. It has a direct and indirect total annual 
turnover of 46 billion Swedish crowns (Remmerth, 2008; Johansson & 
Andersson, 2004), greater than that for the metal and steel industries.  
OA is currently clinically diagnosed late in the disease process, when 
irreversible damages to the cartilage have become evident. Therefore, there is a 
need for the development of reliable molecular markers (also called 
biomarkers) for the early stages of the disease. Optimal biomarkers could be 
used not only for early diagnosis but also for monitoring progression of the 
disease and evaluating treatment effects. To develop these biomarkers, the 
pathogenesis of OA needs to be further elucidated for an understanding of the 
complex molecular mechanisms responsible for the onset, development, and 
advancement of the disease.  
The work included in this thesis focus on the changes of the extra cellular 
matrix in articular cartilage caused by inflammation. 
1.2 Articular cartilage 
Cartilage is a connective tissue consisting of chondrocytes, water, and the extra 
cellular matrix (ECM) synthesised by chondrocytes. Cartilage can be divided 
into hyaline cartilage, fibrocartilage, and elastic cartilage. This thesis examines 
the hyaline articular cartilage outlining the articular surface of bones. 
Adult articular cartilage is an avascular, hypocellular, aneural, and 
alymphatic tissue with limited regenerative capacity (Iwamoto et al., 2013). 
This complex structure, found in all synovial joints allows pain-free, low-
friction joint movement and disperses high mechanical load. Articular cartilage 
is organized in different zones (Figure 1) on the basis of its morphological 
features (Pritzker & Aigner, 2010). The superficial zone is immediately 
subjacent to the joint surface and chondrocytes of this zone are elongated and 
flattened. Underneath the superficial zone is the middle zone where the 
morphology of chondrocytes changes to rounder cells. The deep zone is in 
between the middle zone and the calcified cartilage; here chondrocytes exist as 
round cells in columns. The boundary between uncalcified and calcified 
cartilage is called the tidemark and beneath the calcified cartilage is the 
borderline of subchondral bone called the cement line. The thickness of equine 
articular cartilage varies in different joints; the average thickness of the 
articular cartilage in the MCP and carpal joints is similar (0.86 mm) while the 
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stifle has a thicker articular cartilage (2 mm) (Lee et al., 2014), comparable to 





Figure 1. Morphological structure of articular cartilage, organized in superficial, middle, and deep 
zones. The orientation of the collagen fibres as well as chondrocyte morphology vary in these 
zones. Originally published in “Surgical Alternatives for Treatment of Articular Cartilage 
Lesions”, Journal of the American Academy of Orthopaedic Surgeons, (2000;8(3)-180-189), by 
Browne, E. Jon and Branch, P. Thomas. Reused with permission and license from Lippincott 
Williams and Wilkins/Wolters Kluwer Health, Inc. © 2000, American Academy of Orthopaedic 
Surgeons. 
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1.2.1 Molecular organization of articular cartilage 
Chondrocytes synthesize the ECM as well as produce enzymes responsible for 
degradation of the ECM. Water is the major constituent (approx. 75%) of ECM 
and the remainder is composed of several molecular components interacting to 
form the specialised network – collagens, proteoglycans and non-collagenous 
proteins. The ECM, which embeds the chondrocytes, is organized into zones 
based on their distance from the chondrocyte. Closest to the chondrocyte is the 
pericellular matrix, where molecules from the ECM bind to surface receptors. 
The territorial and interterritorial zones are found at a further distance from the 
chondrocyte (Las Heras et al., 2012; Kvist et al., 2008). The distribution of the 
components in the ECM varies within these zones (Heinegård & Saxne, 2011; 
Heinegård, 2009) (Figure 2).  
 
Figure 2. Illustration of molecular components and their organization in the extracellular matrix 
(ECM) of articular cartilage. The ECM surrounding chondrocytes is arranged into zones 
described by their distance to the cell. The interterritorial matrix closer to the cells and the 
interritorial matrix at a further distance from the cell are indicated. Originally published in 
“Proteoglycans and more - from molecules to biology”, International Journal of Experimental 
Pathology (2009),90,575-586 by Heinegård, D. Reused with permission and license from John 
Wiley & Sons, Inc. ©Dick Heinegård © 2009 Blackwell Publishing Ltd. 
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Collagens 
The collagen network gives cartilage its tensile strength and contributes to 
approximately 60% of the dry weight of articular cartilage. Articular cartilage 
comprises of collagen types II, III, VI, IX, XI and XII, and the organization of 
collagen varies in the different zones of the articular cartilage. In the superficial 
zone, collagens are arranged parallel to the articular joint surface, in contrast to 
the deep zone where the collagen fibres are organized perpendicular to the 
surface. In between these zones (middle zone), the collagen is organized in a 
random way (Figure 1). The superficial zone has the highest content of 
collagen and it decreases with the distance from the surface (Eyre et al., 2006).  
Collagen type II is the most common form of the collagen network in 
cartilage, representing approximately 90% of the total collagen content. 
Collagen type II, which has a fibrillar structure, is synthesized and secreted as 
procollagen α chains containing amino- and carboxy propeptides that are 
cleaved away by amino- and carboxy-terminal proteinases in the ECM 
(Peltonen et al., 1985). Other enzymes, metalloproteinases, (MMPs), cleave the 
mature collagen type II molecule, leading to a decreased content of collagen 
type II (Poole et al., 2002). In OA there is evidence of an attempt to repair 
damage by an increased synthesis (Nelson et al., 1998) of collagen type II, but 
meanwhile there is also an increased degradation of collagen type II (Hollander 
et al., 1994) mediated mainly by MMP -1 and -13 (Dahlberg et al., 2000). 
Fragments resulting from the degradation of collagen type II have been shown 
to induce cartilage degradation by enhancing release of proteolytic enzymes 
(Guo et al., 2009) and thereby increasing the cleavage of both collagen type II 
and aggrecan (Yasuda et al., 2006).  
Collagen type III is a trace component of articular cartilage, but can be 
increased in OA (Tanaka et al., 2013; Eyre et al., 2006). 
Collagen type VI, primarily localized in the pericellular matrix (Zhang et 
al., 2011b), is composed of α-chains (α-1, α-2, α-3) and forms a highly cross-
linked microfibrillar network (Gelse et al., 2003). This type of collagen has 
been found to interact with the chondrocyte by binding to integrins (Marcelino 
& McDevitt, 1995) of the cell membrane, as well as by interacting with other 
ECM molecules, such as collagen type II and small leucine-rich 
proteins/proteoglycans (SLRPs), decorin (Bidanset et al., 1992), and biglycan 
(Wiberg et al., 2002). Collagen type VI is postulated to strengthen the 
complete collagen network by binding to other members of the ECM. In OA, 
the turnover of collagen type VI is increased (Arican et al., 1996) and there is 
evidence of alteration in the molecular distribution (Wilusz et al., 2013) 
compared to normal cartilage. The increased concentration seen in the 
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interterritorial matrix could be the result of degradation of collagen type VI, 
leading to diffusion of fragments from the pericellular area (Soder et al., 2002).   
Collagen type IX can decorate collagen type II fibril surfaces by covalent 
binding (Vaughan et al., 1988), suggesting that it has a role in improving 
mechanical restraint. It is hypothesized to act as a glue for the collagen type II 
network. Collagen type IX consists of three collagenous domains separated by 
four noncollagenous domains and the N-terminal noncollagenous domain 
(NC4) that projects out from the fibril surface can interact with other ECM 
molecules such as cartilage oligomeric matrix protein (COMP) (Holden et al., 
2001). In vivo studies of collagen IX null mouse cartilage have suggested that 
proteins such as matrilin-1, matrilin-4, epiphycan, and thrombospondin-4 
interact with collagen type IX, (Brachvogel et al., 2013). Degradation of 
collagen type IX is seen in the early stages of OA (Diab, 1993). 
Collagen type XI can covalently crosslink to collagen type II and thereby 
support the collagen network, but the collagen type XI molecules can also 
crosslink to each other (Gelse et al., 2003; Eyre, 2002). The importance of this 
type of collagen is suggested by the recent findings of single nucleotide 
polymorphism in the collagen type XIA1 gene that is associated with OA 
(Rodriguez-Fontenla et al., 2014). 
Collagen type XII is a fibril-associated collagen with interrupted triple 
helices, which can connect to other components in the ECM and is thought to 
stabilize the organization of the collagen network (Gregory et al., 2001).  
Proteoglycans 
Proteoglycans contribute to approximately 25-35% of the dry weight of 
articular cartilage and consist of a core protein with attached 
glycosaminoglycan (GAG) chains.  
Aggrecan is the most common proteoglycan in articular cartilage. Through 
its negatively charged chondroitin sulphate chains, it has the potential to bind a 
large amount of water, resulting in a swelling and expansion of the ECM, and 
thereby enabling the cartilage to sustain high compressive load (Heinegård, 
2009).  
Aggrecan is a large (>2500 kDa), aggregating proteoglycan residing in the 
fibrillar collagen network. The superficial zone of articular cartilage has the 
lowest content of aggrecan and the content increases with the distance from the 
surface. The structure of the core protein in aggrecan consists of three globular 
domains called G1, G2 and G3. G1 has the ability to bind to link proteins or 
hyaluronic acid (Hascall & Heinegård, 1974), thereby producing multi-
molecular aggregates. The region between G1 and G2 is called the 
interglobular domain, which contain sites subject to proteolytic cleavage 
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(Sandy et al., 1991) by MMPs or aggrecanases (a disintegrin and 
metalloproteinase with thrombospondin motifs (ADAMTS)), resulting in 
several protease-mediated catabolic epitopes (Struglics et al., 2006). MMP-3 
and -13, as well as other MMPs, cleave aggrecan in the interglobular domain 
between Asn 341 and Phe 342, (Flannery et al., 1992) while ADAMTS-4 and -
5 also cleave aggrecan in the interglobular domain, but between Glu 373 and 
Ala 374 (Tortorella et al., 2002; Tortorella et al., 2000b).  
Between the G2 and G3 domains, glycosaminoglycan side chains can 
attach (first about 30 keratan sulphate chains followed by approximately 100 
chondroitin sulphate chains). Moreover, aggrecan also contains a variable 
number of O- and N-linked oligosaccharides. There are several ADAMTS-4 
and -5 mediated cleavage sites in between the G2 and G3 domains (Heinegård, 
2009). 
Non-collagenous matrix proteins  
Non-collagenous proteins contribute to approximately 15-20% of the dry 
weight of articular cartilage.  
The SLRPs family has 18 members to date, including: biglycan, 
chondroadherin, decorin, epiphycan, fibromodulin, lumican and 
proline/arginine-rich-end leucine-rich repeat (PRELP) found in cartilage. 
These horseshoe-shaped proteins have a molecular structure that consists of an 
N-terminal variable domain and a conserved domain of tandem leucine-rich 
repeats (Ni et al., 2014). This distinctive structure benefits protein-protein 
interactions, enabling binding to various growth factors, cytokines, cell surface 
receptors, and other ECM components, thereby affecting various signalling 
pathways (Schaefer & Iozzo, 2008). SLRPs exhibit many biological roles; key 
features of SLRPs in joints are their involvement in tissue development and 
assembly. The function of SLRPs in collagen fibrillogenesis has been studied 
in developing mice tendons (Reed & Iozzo, 2002; Ezura et al., 2000). SLRPs 
are also involved in modulation of fibril formation by interacting with 
collagens (Kalamajski & Oldberg, 2010), to construct a specific collagen 
matrix for a functioning ECM.  
The involvement of SLRPs in the pathogenesis of OA is hypothesized to 
occur by several mechanisms. A loss of SLRPs can lead to undesirable changes 
in the ECM collagen network. The SLRPs can also modulate transforming 
growth factor (TGF)-β signalling and thereby affect 
proliferation/differentiation of chondrocytes, or they can interact with the 
innate immune system by activating or inhibiting the complement cascade. As 
an example, fibromodulin can bind to C1q and activate the classical component 
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system (Sjoberg et al., 2005) while the binding of biglycan to C1q inhibits the 
activation of the classical complement system (Groeneveld et al., 2005)  
Matrilins, another type of noncollagenous proteins found in cartilage, are 
considered to be adaptor proteins, which support the ECM assembly by 
binding to aggrecan, SLRPs, and collagen fibrils (Klatt et al., 2011).   
COMP, also called thrombospondin-5, is a fundamental part of the ECM in 
articular cartilage. This 524 kDa multidomain glycoprotein consists of five 
identical units (Oldberg et al., 1992) forming a pentameric structure (Figure 3). 
COMP can bind to collagen types I and II (Rosenberg et al., 1998) and 
catalyze fibril formation by interacting with free collagen I and II molecules, 
bringing these molecules into close proximity with each other to promote 
further assembly (Halasz et al., 2007). COMP can also interact and bind to 
collagen type IX (Holden et al., 2001), aggrecan (Chen et al., 2007), matrilins 
(Mann et al., 2004) and fibronectin (Di Cesare et al., 2002). COMP is found in 
other structures of the joint such as tendon (Sodersten et al., 2013; Smith et al., 
1997). Mutations in COMP can lead to chondrodysplasias, leading to early 
onset OA and short-limb dwarfism (Briggs et al., 1998). COMP is considered 
to be a marker of cartilage metabolism. It is studied as a potential diagnostic 
and prognostic biomarker for OA because serum levels of COMP are elevated 
in human OA (Valdes et al., 2014; Verma & Dalal, 2013; Clark et al., 1999). 
COMP has an active role in inflammation by activating the alternative pathway 
and inhibiting the lectin- and classical-complement pathways in rheumatoid 
arthritis (RA) patients but not in OA patients (Happonen et al., 2010). This 
suggests that the specific and likely disease-dependent fragmentation of COMP 







Figure 3. Schematic structure of one subunit of COMP and the interaction between pentameric 
COMP and collagen type II. COMP consists of five identical subunits, each with epidermal 
growth factor (EGF) repeats and type 3 repeats (calcium binding domains/calmodulin type units). 
The coiled-coil pentamerization domain is held together by disulphide bonds to form a pentameric 
structure. The function of the globular domain is to bind to other members of the ECM. The high-
affinity binding between COMP (via the carboxyterminal domain) and native triple-helical 
collagen type II affects collagen fibril assembly. The COMP molecule can bind to five collagen 
molecules and facilitate their interaction in accelerating collagen fibril formation (Halasz et al., 
2007). COMP can also interact with other collagens of the ECM such as collagen IX, further 
stabilizing the collagen network. (Illustration by E.Svala) 
The mucin-like glycoprotein lubricin, also known as proteoglycan-4, is 
found in synovial fluid where it acts as a boundary lubricator (Swann et al., 
1977) and protector (Rhee et al., 2005b) of articular cartilage. The molecular 
structure of the protein consists of somatomedin B-like-domains at the N-
terminus, followed by several mucin-like repeats which are heavily 
glycosylated. It ends with a hemopexin-domain at the C-terminus (Rhee et al., 
2005b). It is synthesized and secreted by the chondrocytes of the superficial 
zone of articular cartilage (Schumacher et al., 1994), but is also found in 
several other structures of the joints such as tendons (Funakoshi et al., 2008) 
and menisci (Zhang et al., 2011a). The reduction of coefficient-of-friction is 
associated with inhibition of chondrocyte apoptosis (Waller et al., 2013). 
Lubricin attaches to denaturated, amorphous and fibrillar collagen at the 
articular cartilage surface (Chang et al., 2014). Lubricin can present various O-
glycan structures, which are proposed not only to have a role in lubrication 
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(Jay et al., 2001), but also in inflammation. They contribute to inflammation by 
carrying inflammatory oligosaccharide epitopes (Estrella et al., 2010) and 
binding to peripheral and synovial polymorphonuclear granulocytes (Jin et al., 
2012). 
1.3 Joint structure changes in osteoarthritis 
In racehorses, the MCP joint is the one most commonly affected by OA, 
followed by the carpal joint (Figure 4) (McIlwraith et al., 2012).  
The equine MCP joint is a hinge joint consisting of the distal metacarpal bone 
III and the proximal phalanx bone (Fails & Kainer, 2011). The MCP has a 
close-fitting articular surface that can quickly develop linear erosions and wear 
lines in association with osteochondral fragmentation (McIlwraith et al., 2012). 
This is possibly due to the small joint surface, wide range of motion, and 
weight transmission (Pool & Meagher, 1990). 
The equine carpal joint is comprised of three joint compartments; the 
radiocarpal, midcarpal, and carpometacarpal. The middle carpal joint is 
overextended during the weight-bearing phase of the stride (Bramlage et al., 
1988) where it is  exposed to high load, particularly on the radial facet of the 
third carpal bone. During trotting and galloping, it is exposed to forces in both 
longitudinal and transversal directions (Johnston et al., 1997; Bramlage et al., 
1988). The dorsal radial facet (DRF) of the third carpal bone (C3) is a contact 
area with higher mechanical load compared to the palmar condyle (PC) of this 





Figure 4. The location of the equine metacarpophalangeal (MCP) and carpal joints, which are the 
joints most commonly affected by OA (McIlwraith et al., 2012). The dorsal radial facet (DRF) of 
the third carpal bone (C3) is a contact area with higher mechanical load compared to the palmar 
condyle (PC) of this bone which is a noncontact area (Palmer et al., 1994).                          
Drawings by Alexandra Leijon. 
OA affects not only articular cartilage, but also the other components of the 
joint (McIlwraith et al., 2010), where it leads to formation of subchondral bone 
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sclerosis (Grynpas et al., 1991), formation of new bone at the joint margins 
(osteophyte formation) (Olive et al., 2009), increased bone remodeling (for 
review see (Li et al., 2013), and synovitis (Myers et al., 1990). These joint 
tissue changes are similar among species, including man. 
Chondrocyte necrosis with adjacent chondrocyte cluster formations (Lotz et 
al., 2010), superficial fibrillation/fraying and cleft formations are seen in the 
pathological destruction of articular cartilage (McIlwraith et al., 2010). The 
mechanism behind the increased number of cell clusters (Poole et al., 1991), 
seen in OA cartilage, is thought to be proliferation (Pfander et al., 2001) and/or 
migration (Kouri et al., 1996). There is also a change of phenotype of 
chondrocytes in OA cartilage, resulting in hypertrophic cells (von der Mark et 
al., 1992). This hypertrophy is characterized by collagen X and MMP-13 
expression (Nurminskaya & Linsenmayer, 1996).  
A hallmark of OA is the degradation of components in the ECM (Heinegård 
& Saxne, 2011). Normal articular cartilage has a low metabolic activity with a 
low-turnover rate of ECM, delicately regulated through anabolic (production of 
ECM molecules) and catabolic events (degradation of ECM) (Henrotin & 
Reginster, 1999). In early OA, there is an initial attempt at repair, reflected by 
an elevated anabolic activity of the chondrocytes, with cell proliferation and 
synthesis of ECM molecules and growth factors (Poole et al., 2007). However 
this activity is later disrupted and overrun by the catabolic events, ultimately 
leading to a net loss of ECM.  
Degradation of collagen type I, II and III molecules occurs through an 
initial cleavage into ¾- and ¼-length fragments by proteolytic enzymes called 
collagenases. MMP-13 is an important collagenase in the breakdown of 
collagen type II (Billinghurst et al., 1997), but chondrocytes are capable of 
producing and secreting several other proteins in the MMP family. 
Chondrocytes of human OA cartilage produce MMP-1, -2, -3, -8, -9 and -13 
(Tetlow et al., 2001). The general MMP activity is increased in synovial fluid 
from equine OA joints (van den Boom et al., 2005; Brama et al., 2004; Brama 
et al., 2000) and messenger ribonucleic acid (mRNA) gene expression of 
MMP-13 is elevated in synovial tissues and cartilage from equine OA joints 
compared to normal joints (Kamm et al., 2010). In vitro studies have 
demonstrated this, since cytokine-stimulated bovine (Sondergaard et al., 2006) 
and equine (Clutterbuck et al., 2011; Clegg & Carter, 1999) articular cartilage 
cause an increase in the secretion of proteolytic enzymes (MMP-1, -2, -3, and -
9). This in turn leads to the degradation and secretion of collagen and 
proteoglycan fragments into the cell media. Other proteolytic enzymes, 
ADAMTS-5 (Little et al., 2007; Stanton et al., 2005) and ADAMTS-4 
(Tortorella et al., 2000a), also have an important role in the degradation of 
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equine cartilage. Several in vitro studies of articular cartilage explants have 
revealed a distinct degradation pattern due to inflammatory stimuli, where 
aggrecan is released early, followed by COMP, fibromodulin and finally, 
collagen type II (Williams et al., 2013; Heathfield et al., 2004; Dickinson et 
al., 2003; Sztrolovics et al., 1999).  
1.3.1 Osteochondral fragments 
Osteochondral fragments (OCFs), also known as chip fractures, are found at 
the dorsal aspects of the articular margins and facets of bones in the carpal 
joints and the proximal aspect of the first phalanx. They are thought to arise 
from fractured osteophytes, degenerated articular cartilage or necrotic 
subchondral bone in racehorses with OA (Pool & Meagher, 1990). The 
metabolic activity in the OCFs of the carpal joints appears elevated, as 
indicated by increased levels of native COMP in synovial fluid from racehorses 
with OCFs (Arai et al., 2008; Skiöldebrand et al., 2005) and an increased 
synthesis of aggrecan in serum and synovial fluid (Frisbie et al., 1999) . COMP 
synthesis is also seen in the chondrocytes, by in situ hybridisation, in these 
OCFs (Skiöldebrand et al., 2005). High levels of interleukin (IL)-6, but not 
TNF-α are found in the synovial fluid of carpal joints with OCFs (Ley et al., 
2007), with the chondrocytes being the potential source of IL-6 (Ley et al., 
2009). 
1.4 Factors involved in the development of OA 
OA is thought to be a multifactorial disease with mechanical loading being one 
of the factors that promotes it. Normal healthy cartilage has specialized 
biomechanical properties which allow it to spread force between joints while 
providing nearly friction-free movement (Kerin et al., 2002). Excessive 
mechanical load or a major traumatic event alters the physiological 
biomechanical environment by activating factors involved in the pathogenesis 
of OA. These factors include inflammatory mediators and proteolytic enzymes, 
which induce ECM degradation and chondrocyte death (Buckwalter et al., 
2013). The extensive training that racehorses undergo provokes metabolic 
changes in the composition of the ECM, with decreased synthesis and release 
of COMP (Skiöldebrand et al., 2006). These changes are seen in in vitro 
studies where static compression stimulates a degradation of proteoglycans and 
collagens in bovine cartilage (Loening et al., 2000) and decreases the synthesis 
of cartilage matrix proteins. On the other hand, dynamic compression increases 
the synthetic activity of chondrocytes (Tsuang et al., 2008; Kim et al., 1994) 
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OA can occur early in equine athletes; however, it can also develop later in 
older horses (McIlwraith et al., 2012). A prominent risk factor associated with 
OA is aging; the prevalence of human OA also rises with age. Age-related 
changes of ECM are degradation of collagen with an increased fibrillation of 
the articular surface (Hollander et al., 1995) and extensive heterogeneity in the 
molecular structure of the ECM (Dudhia, 2005). Furthermore, the chondrocyte 
anabolic activity decreases with age (Aigner et al., 2007). Nevertheless, since 
not all older horses/humans develop OA, the link between OA and ageing is 
not fully elucidated.  
Another risk factor associated with OA is genetics. Proposed susceptibility 
candidate genes for human OA are linked to ECM or signalling molecules 
thereof, e.g., RUNX2, SMAD3 and growth differentiation factor-5 (GDF-5) 
(Reynard & Loughlin, 2013). There is emerging evidence of a link between 
obesity and the initiation and progression of human OA with possible 
contributions from both increased mechanical forces across joints, leading to 
cartilage destruction, and from systemic factors such as altered adipokine 
levels (Poonpet & Honsawek, 2014; Zhou et al., 2014; Spector et al., 1994).  
1.5 Inflammation 
Inflammation is strongly associated with the pathophysiology of both human 
(Saxne et al., 2003; Pelletier et al., 2001) and equine OA (Kamm et al., 2010); 
a diversity of inflammatory mediators, such as cytokines, control the 
inflammatory process. Inflammatory signs seen in the development and 
progression of OA are clinical local signs such as joint pain, swelling, stiffness, 
an increased level of C-reactive protein (Jin et al., 2013; Pearle et al., 2007; 
Sharif et al., 2000), and synovitis (Sellam & Berenbaum, 2010; Sutton et al., 
2009) with increased synovial mononuclear cell infiltration (Benito et al., 
2005). An inflamed synovial membrane can produce various inflammatory 
mediators, such as IL-1β and tumor necrosis factor (TNF)-α; the chondrocytes   
respond by producing proteolytic enzymes. However, OA chondrocytes also 
produce and secrete several inflammatory mediators themselves including: IL-
β, TNF-α, (Tetlow et al., 2001), IL-6 (Ley et al., 2009), IL-7 (Long et al., 
2008), IL-18 (Olee et al., 1999), and HMGB-1 (Terada et al., 2011). The 
inflammatory cytokines are the most important compounds participating in the 
pathogenesis of OA; their involvement disrupts the normal metabolic 
homoeostasis of cartilage by favouring catabolic processes, with MMP-
activation leading to destruction of cartilage (Wojdasiewicz et al., 2014). 
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1.5.1 Interleukin-1β and Tumor necrosis factor-α 
IL-1β and TNF-α are often regarded as the master cytokines involved in the 
pathogenesis of OA. IL-1β is synthesized in a pro-form (pro-IL-1β) that is 
cleaved by casphase-1 (Piccioli & Rubartelli, 2013) to generate an active form  
before it is secreted by chondrocytes and synovial cells into the joint cavity. 
Pro-IL-1β can also be found extracellular where it can be cleaved by serine 
proteases (Wittmann et al., 2011). 
Enhanced levels of IL-1β are found in cartilage, bone, synovial fluid and 
synovial membrane in human OA (Massicotte et al., 2002; Melchiorri et al., 
1998; Kubota et al., 1997; Farahat et al., 1993), as well as in articular cartilage 
(Kamm et al., 2010) and synovial fluid (Morris et al., 1990) in equine OA 
joints. Increased levels of the membrane bound receptor, IL-1 receptor type I, 
which activates the intracellular signalling cascade upon binding to IL-1β, is 
found in human OA chondrocytes (Silvestri et al., 2006). The IL-1 receptor 
accessory protein is also necessary for signalling (Casadio et al., 2001).  IL-1β 
can also bind to a decoy receptor called IL-1 receptor type II; however, this 
binding does not generate active signalling, and the abundance of this receptor 
is reduced in human OA chondrocytes (Wang et al., 2003). Another 
counterproductive molecule, the receptor antagonist IL-1Ra, can bind to both 
receptors of IL-1β to inhibit the binding of IL-1β and subsequent signalling. In 
an established equine OA model, gene transfer of IL-1Ra displays favourable 
effects with upregulation of IL-1Ra protein expression, improvement in pain 
and disease activity, and positive effects on histologic parameters in the 
articular cartilage (Frisbie & McIlwraith, 2000). 
There are several effects of active IL-1β signalling in cartilage. The 
activation of numerous signal transduction pathways leads to an increase in 
intracellular Ca2+, with activation of protein kinase C, p38, c-JUN N-terminal 
kinase, and extracellular signal regulated kinase -1 and -2. Active IL-1β 
signalling also leads to nuclear translocation of nuclear factor-κB (NF-κB), 
activating transcription factor, and activator protein 1 (Daheshia & Yao, 2008). 
Activation of these transcription factors results in expression of genes leading 
to the production of MMPs and ADAMTs (Tetlow et al., 2001), prostaglandin, 
and nitric oxide. There is also an induction of the production of other cytokines 
such as IL-6 and to an even greater degree IL-1β, suggesting an autocrine loop 
(Fan et al., 2007). 
Taken together, the effects of IL-1β on chondrocytes induce the expression 
of catabolic genes. The effects also include downregulation of the expression 
of anabolic genes involved in the metabolism of chondrocytes and induction of 
chondrocyte apoptosis (Wojdasiewicz et al., 2014; Daheshia & Yao, 2008).  
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TNF-α is synthesized as a homotrimeric tramsmembrane protein type II that 
needs to be cleaved by metallopeptidase TNF-α converting enzyme (also called 
ADAM-17), for activation (Black et al., 1997). The secretion and presence of 
TNF-α in human OA is very similar to that of IL-1β, as they are secreted by the 
same cells in the joint and are elevated in human OA cartilage, subchondral 
bone, synovial membrane, and synovial fluid (Wojdasiewicz et al., 2014). This 
suggests that there is a synergistic interaction between them (Henderson & 
Pettipher, 1989). The concentration of TNF-α is increased in synovial tissue 
and articular cartilage of equine OA (Kamm et al., 2010). Other studies report 
that TNF-α concentrations in synovial fluid are not related to equine OA (Ley 
et al., 2007; Jouglin et al., 2000) suggesting that TNF-α is not a master 
cytokine in the disease. TNF-α can bind to two receptors, called TNFR-1 and 
TNFR-II, (Westacott et al., 1994) and active TNF-α signalling can inhibit 
proteoglycan (Saklatvala, 1986) and collagen synthesis (Seguin & Bernier, 
2003) as well as produce MMPs (Wojdasiewicz et al., 2014).  
 
1.5.2 Interleukin-6 
IL-1β induces a massive production of IL-6 (Nietfeld et al., 1990). Although 
IL-6 is called a pro-inflammatory cytokine, this is somewhat misleading 
because IL-6 has several anti-inflammatory, protective effects such as 
inhibiting the synthesis of IL-1β and TNF-α and enhancing the production of 
cortisol (Mölne & Wold, 2007). Classical signalling acts through binding of the 
membrane-bound IL-6 receptor. The membrane-bound IL-6 receptor system 
consists of two membrane proteins: a ligand-binding chain (IL-6R) and a 
membrane-bound β-receptor glycoprotein, gp130. Binding of IL-6 to IL-6R 
triggers the association of IL-6R and gp130, and gp130 in turn transduces the 
signal (Kishimoto, 1992). IL-6 can also bind to another receptor, the soluble 
IL-6 receptor, and the signalling through this receptor is called trans-signalling. 
In trans-signalling, IL-6 binds to soluble forms of the IL-6R (sIL-6R) and this 
complex activate cells due to the uniform expression of gp130 (Wolf et al., 
2014). A protective role for IL-6 against the pathogenesis of OA has been 
suggested because IL-6 gene-knockout mice develop more advanced 
osteoarthritis (de Hooge et al., 2005). Also, high levels of IL-6 have been 
detected in synovial fluid in canine OA (Venn et al., 1993) and in equine OA 
synovium (Ley et al., 2009). 
1.5.3 High-mobility group box protein-1 (HMGB-1) 
HMGB-1 is a 25 kDa chromosomal protein, consisting of two basic boxes 
(called A and B) responsible for DNA binding, and a highly acidic C-terminus 
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(Zhang & Wang, 2010). The protein has different functions depending on the 
intracellular or extracellular location. In the nucleus it facilitates binding of 
regulatory proteins, with a role as a minor-groove binding enhancer (Lotze & 
Tracey, 2005). Extracellularly, HMGB-1 acts as a danger-associated molecular 
pattern (DAMP) molecule, released by necrotic cells or secreted in response to 
inflammatory stimuli, thereby mediating activation of innate immune response 
(Castiglioni et al., 2011). HMGB-1 is expressed in synovial tissue from RA 
patients and from rats with experimental arthritis (Kokkola et al., 2002). 
HMGB-1 levels in synovial fluid of knee-OA patients are associated with 
radiographic disease severity (Li et al., 2011) and HMGB-1 is overexpressed in 
human (Garcia-Arnandis et al., 2010) and equine OA synovium (Ley et al., 
2009). Additionally in vitro stimulation with IL-1β upregulates the mRNA 
gene expression of HMGB-1 and promotes the translocation of HMGB-1 from 
nuclei to cytoplasm in human OA chondrocytes (Terada et al., 2011).  
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2 Aims of the thesis 
The overall aim of the thesis was to contribute to knowledge about the 
influence of inflammatory cytokines on equine articular cartilage. 
 
The specific objectives of this thesis were to: 
 
1) Establish a three-dimensional (3D) culture system (pellets) for equine 
chondrocytes as an in vitro model for OA.  
 
2) Evaluate and compare the effect of the cytokines interleukin (IL) –1β, 
IL-6 and HMGB-1 on equine articular chondrocytes cultured in an in 
vitro 3D model. 
 
3) Examine if IL-6 could induce an upregulation of GDF-5 in equine 
chondrocytes and to identify the possible signalling pathways.  
 
4) Investigate the presence of GDF-5 expressing chondrocytes in normal 
equine articular cartilage and OCFs. 
 
5) Investigate the secretome of equine articular cartilage explants   
stimulated with IL-1β and cultured in vitro with the aim of describing 
the longitudinal release pattern of ECM molecules. 
 
6) Study the presence and glycosylation profile of lubricin in synovial 
fluid from horses with OA and normal joints and to examine the 
secretion pattern of lubricin, after IL-1β stimulation, in equine 




Two different in vitro models were used with the purpose of mimicking OA in 
vivo. Chondrocyte pellets and explants derived from healthy equine articular 
cartilage were stimulated with cytokines to induce an inflammation and the 
analyses were done by: immunohistochemistry, immunoassays (ELISAs, 
Western blot), biochemical assays (glycosaminoglycan content), quantification 




Hypotheses for the studies on equine chondrocyte pellets in vitro were: 
  
! Paper I: Chondrocyte metabolism is affected by exposure to IL-1β, IL-6 and 
HMGB-1. The response can be different in chondrocytes cultured from 
differently loaded anatomical sites in vivo from the equine third carpal 
bone. 
 
! Paper II: IL-6 induces an upregulation of GDF-5 in equine OCFs explaining 
the anabolic processes found in the fragments in vivo. Expression of GDF-5 
is affected by short and long term stimulation of IL-1β and IL-6 in 
chondrocytes from the third carpal bone.  
 
Hypotheses for studies on equine cartilage explants in vitro were: 
 
! Paper III: Molecular changes in equine cartilage after IL-1β stimulation are 
time dependent.  
 
! Paper IV: Inflammation in OA influences lubricating properties by altering 
the level and glycosylation profile of lubricin in equine articular cartilage. 
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4 Material and methods 
This section summarizes the material and methods of the studies for this thesis. 
Detailed descriptions of the procedures are presented in each of the papers. 
4.1 Animals and sample collection (papers I-IV) 
Macroscopically normal articular cartilage was aseptically obtained from the 
DRF (paper I and II) and PC (paper I) of the C3 from euthanized horses 
without any clinical history of joint disease. Additional osteochondral 
fragments (OCF) (dorsoproximally of the radial facet of C3, dorsodistally of 
the radial carpal bone, or dorsoproximally of the first phalanx) were used from 
three horses that underwent arthroscopy because of lameness (paper II). Full-
thickness articular cartilage explants from the weight-bearing part of the distal 
metacarpal bone III in the MCP joint from three slaughtered horses without 
any clinical history of joint disease, were used in papers III-IV. All collected 
samples were transported chilled to the cell culture lab in a sterile saline 
solution (0.9% sodium chloride) with 50 mg/l gentamin sulphate and 250 
µg/ml amphotericin B. 
Synovial fluid (paper IV) was aseptically collected from middle carpal joints 
with macroscopically normal articular cartilage (n=7), structural OA lesions 
(n=7), and OCF (n=3). 
4.2 Isolation and expansion of chondrocytes (papers I-II) 
Protocols for isolation and expansion of chondrocytes from articular cartilage 
were performed according to previously described procedures (Brittberg et al., 
1994). In summary, equine articular cartilage shavings were washed with cell 
culture media and mechanically minced with a scalpel. Enzymatic digestion 
with 0.8 mg/ml collagenase type 2 was performed for 20-24 h at 37°C in 7% 
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CO2/93% air, and a viable count of the single cell solution was performed with 
0.4% tryptan blue dye in a Bürker chamber. Cells were seeded into culture 
flasks at a density of 16,000 cells/cm2 in complete chondrocyte media 
(Dulbecco’s Modified Eagle medium, i.e., nutrient mixture F-12 (DMEM/F12) 
supplemented with 1x penicillin-streptomycin (PEST), 2 mM L-glutamine, 0.1 
mg/ml ascorbic acid and 10% equine serum) and incubated at 37°C in 7% 
CO2/93% air. 
At approximately 80% confluence, the chondrocytes were treated with 
0.05 % trypsin with 1x ethylenediaminetetraacetic acid (EDTA) at 37°C in 7% 
CO2/93 % air until the cells detached from the cell culture flasks. Chondrocytes 
were seeded into sterile polystyrene cell-culture flasks at a density of 3000 
cells/cm2 in complete chondrocyte media at 37°C in 7% CO2/93 % air until 
80% confluence. Medium was changed twice a week.  
4.3 In vitro chondrocyte culture models (papers I,II,III,IV) 
4.3.1 Three-dimensional chondrocyte pellet cultures (papers I-II) 
 
Figure 5. Experimental setup for three-dimensional (3D) pellets cultured in vitro. Normal equine 
articular cartilage was harvested from the third carpal bone in the middle carpal joint. 
Chondrocytes were isolated and expanded in monolayer until 80% confluence. Chondrocytes 
were cultured in 3D pellets (200,000 cells/pellet) for 14 days before cytokine stimulation for 1, 2, 
12 or 48 hours. Cell media and 3D pellets were analysed for gene and protein expression. 
Illustration by E.Svala. 
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The protocol for 3D chondrocyte pellet cultures was slightly modified from 
previously described procedures (Stenhamre et al., 2008; Tallheden et al., 
2004). Expanded chondrocytes from the first subculture (passage 1) were 
cultured in 3D pellets in a 96-well ultralow attachment plate, for 14 days at 
37°C in 7% CO2/93% air. Pellet medium was changed daily after 3D 
chondrocyte pellet formation was established (Figure 5).  
4.3.2 Explant cultures (paper III-IV) 
Cartilage explants (5 mm in diameter) were allocated to groups of 4 
explants/well into polystyrene plates. The explants were pre-incubated before 
cytokine stimulation for 24 h, in 2 ml DMEM/F12 supplemented with 0.1 
mg/ml cell-culture-tested bovine serum albumin (BSA), 0.1 mg/ml ascorbic 
acid and 4% v/v PEST at 37°C in 7% CO2/93% air (Figure 6).  
 
Figure 6. Methodological setup for in vitro culture of equine articular cartilage explants. 
Macroscopically normal cartilage from three horses was harvested from the weight-bearing part 
of the distal metacarpal bone III in the metacarpophalangeal joints. Cartilage explants (5 mm in 
diameter) were cultured in culture dishes with or without IL-1β during 25 days. Culture medium 
was changed and harvested every third day. Analyses performed on cell culture media were: 
quantitative proteomics, GAG, Western Blot (for COMP and Lubricin) and Elisa (for MMP-13 , 
C1, 2C and Lubricin). At day 25, the cartilage explants were harvested for histological evaluation 
(hematoxylin and eosin (H&E), toluidine blue and safranin O). Illustration by E.Svala. 
4.3.3 Cytokine stimulation (paper I-IV) 
At day 14 of chondrocyte culture, the pellets (papers I, II) were allocated with 
a randomized procedure to treatment groups and either stimulated with 
 37 
recombinant equine IL-1β (5 ng/ml), recombinant equine IL-6 (5 ng/ml), 
recombinant human HMGB-1 (1 µg/ml) or left unstimulated. Medium change 
was performed daily and pellets were stimulated for 1, 2, 12 or 48 hours.  
After the pre-incubation of cartilage explants (papers III, IV) for 24 h, the 
medium was harvested and the explants were cultured in 2 ml medium in the 
presence or absence of 10 ng/ml equine recombinant IL-1β (10 ng/ml) at 37°C 
in 7% CO2/93 % air. The medium was changed and harvested at 3, 6, 9, 12, 
15, 18, 22 and 25 days and immediately frozen at -80°C for later analysis.  
Pellets or explants were harvested and washed in phosphate buffered saline 
(PBS) or snap frozen in liquid nitrogen before storage at -80°C or fixed in 
buffered formalin. 
4.4 Histological methods (papers I,II,III) 
4.4.1 Fixation  
Chondrocyte pellets were fixed in 6% v/v neutral buffered formalin, for a 
minimum of 24 h. Normal articular cartilage, OCFs, and cartilage explants 
were immersed in 10 % v/v neutral-buffered formalin and OCFs were 
decalcified in formic acid before embedment.  
4.4.2 Histological stainings (papers I,II,III) 
Sections from central parts of pellets or explants, normal articular cartilage and 
OCFs were dehydrated, embedded in paraffin blocks, cut into 3-6 µm thick 
sections, and stained with hematoxylin and eosin (H&E), safranin-O or 
Massons trichrome. A minimum of two sections/samples was evaluated. 
4.4.3 Immunohistochemical stainings (paper I-II)  
Sections were deparaffinised, rehydrated and immersed in 0.1% v/v detergent 
solution (GDF-5 in paper II) or immersed in 3% v/v hydrogen peroxide to 
quench endogenous peroxidase activity. Samples were then incubated with 
hyaluronidase (COMP in paper I) or subjected to heat-mediated antigen 
retrieval steps (GSK3β and β-catenin staining in paper II). 
Subsequently, non-specific antibody binding was blocked using species-
appropriate serum or BSA before incubation with primary antibodies (rabbit-
anti-bovine COMP, polyclonal goat GDF-5, rabbit polyclonal GSK3β, mouse 
monoclonal nuclear-dephosphorylated β-catenin) at 4°C overnight. Washing 
was performed with PBS or 0.1% v/v detergent solution and an additional 
blocking were performed before incubation with secondary antibodies at room 
temperature. Antibodies were either conjugated with horseradish-peroxidase 
(HRP) (for GSK3β and β-catenin), biotinylated (for COMP) or labelled with 
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photostable orange fluorescent dye (for GDF-5). Avidin–biotin–peroxidase 
complexes were visualized using 3,3´diaminobenzidine. HRP conjugated 
antibodies were detected with a signal amplification kit using fluorophore 
labelling. Nuclei were stained with the fluorescent dye 4', 6-diamidino-2-
phenylindole dihydrochloride (DAPI), or counterstained with Mayer’s 
hematoxylin. Immunostaining was qualitatively assessed using light 
microscopy or fluorescent microscopy with appropriate filters. Isotype control 
antibodies, which have no relevant specificity, were used to distinguish non-
specific background binding from antigen-specific antibody binding. 
4.5 Gene expression analyses 
4.5.1 RNA isolation and quantification (papers I,II) 
Frozen chondrocyte pellets were disrupted through high-speed shaking for 8 
min in 2 ml plastic tubes with tungsten carbide beads. Lysis reagent was added 
to each sample and the shaking was performed again for 2 min. The 
homogenate was incubated at 5 min at room temperature before adding 
chloroform, then shaken vigorously for 15 sec. Samples were incubated at 
room temperature for 3 min and thereafter centrifuged for 15 min at 4°C. The 
upper aqueous phase of the sample was transferred into a new sample tube and 
total RNA was further purified using a commercially available kit and a fully 
automated sample preparation robot, in accordance with the manufacturer’s 
protocol for animal cells. DNase was added to the isolated total RNA. After 
quantity and quality assessments, the recovered total RNA was stored at -80°C. 
4.5.2 Complementary DNA synthesis 
A commercially available reverse-transcription kit was used to prepare 
complementary DNA (cDNA) from 100 ng of total RNA from each 
chondrocyte pellet sample. A thermal cycler program of 25°C (10 min), 37°C 
(120 min), 85°C (5 min), 4°C (∞) was performed and the cDNA (concentration 
5 ng/µl) was stored at -20°C.  
4.5.3 Quantitative real time polymerase chain reaction (qRT-PCR) 
The polymerase chain reaction (Saiki et al., 1985) theoretically amplifies DNA 
exponentially, doubling the number of target molecules with each 
amplification cycle. The thermal cycler protocol for the qRT-PCR reaction 
starts by activating the enzyme uracil-DNA glycosylase at 50°C for 2 min 
followed by activation of DNA polymerase at 95°C for 10 minutes.  




1) Denaturation (95°C for 10 seconds): Double-stranded DNA denatures 
to single-stranded by disrupting hydrogen bonds between 
complementary bases. 
2) Annealing/extension (60°C for 1 minute): The primers anneal 
(hybridize) to the complementary DNA sequences. After annealing, 
DNA polymerase synthesizes a new DNA strand with 
deoxyribonucleotide triphosphates (dNTPs). The new strand will be 
complementary to the DNA template strand.  
 
The amount of DNA is measured after each cycle by attaching the template 
to a fluorescent probe (consisting of an oligonucleotide with a fluorophore (6-
carboxyfluorescein FAM)) at the 5´end and a quencher 
(dihydrocyclopyrroloindole tripeptide minor groove binder, MGB) at the 
3´end. As long as the fluorophore and the quencher are in proximity of each 
other by being attached to the probe, the reporter dye is quenched. The DNA 
polymerase will cleave this reporter dye off the probe (Holland et al., 1991) 
during each extension. This increases the fluorescent signal in direct proportion 
to the number of the number of PCR products (also called amplicons) 
generated. The qRT-PCR reagent solution contains a passive reference dye 
(ROX), used to normalize the reporter fluorescence.  
qRT-PCR protocol 
The quantitative real-time polymerase chain reaction (qRT-PCR) was analysed 
on 2.5 ng cDNA/sample in duplicate with a solution of polymerase, primers, 
probes, nucleotides and buffer in a 96-well reaction plate. A negative control 
without any sample was used to detect contaminating DNA from the reagents. 
The relative gene expression was determined by the 2 –(ΔΔCT) method (Livak & 
Schmittgen, 2001).  
Primers and probes 
A commercially available qRT-PCR assay mix of primers and probes intended 
for the detection of human genes was used for detection of GDF-5, Sry-related 
high-mobility group box 9 (SOX-9) and collagen type II. A basic local 
alignment search tool was used to verify homology between the human and 
equine genes. A database and genome browser were used to select equine-
specific primer and probe sequences for collagen type I, versican, aggrecan, 
COMP, MMP-9, MMP-13, ADAMTS-5, TIMP-1, and beta glucuronidase 
(GUSB). A validation experiment was performed for each equine-specific 
primer and probe set with a dilution series of cDNA template for the target 
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genes. Several potential reference genes were validated (unpublished data) and 
equine GUSB was used as a reference gene. 
4.5.4 Microarray (paper II) 
 
High-throughput gene expression microarrays have been developed during the 
last twenty years and the technology is based on the ability of DNA (on an 
array) to specifically bind/hybridize to complementary sequences (RNA or 
DNA target molecules) from samples (Forster et al., 2003). In paper II we used 
Affymetrix® human gene 1.1 ST microarrays on which millions of short 
strands (approximately 25 bases) of DNA (called oligonucleotide probes) are 
built onto a glass chip, one base at a time. A solution of RNA or DNA from 
samples, labelled with biotin, and a fluorescent stain is distributed over the 
array. When RNA or DNA from the samples binds to the probe on the array 
this results in a fluorescence signal; screening for this hybridization shows if a 
gene is expressed. Highly expressed genes give stronger fluorescence signals 
than genes with lower expression.  
At the time of the experiments in paper II, no equine specific arrays were 
commercially available. Human microarrays had previously been used to study 
the transcriptome of equine chondrocytes in monolayer (Graham et al., 2010) 
and therefore a similar approach was used in paper II.  
Total RNA (250 ng) from chondrocyte pellets was processed and analysed 
with a human microarray for global transcriptome quantification at the 
Nottingham Arabidopsis Stock Centre (University of Nottingham, United 
Kingdom). Briefly, target preparation from total RNA used T7 primers in the 
cDNA synthesis step, followed by in vitro transcription to produce cRNA. 
Random primers were then used to synthesize cDNA from the cRNA. The 
cDNA was fragmented, biotin-labeled, and mixed into a hybridization cocktail 
before application to the array. The high-throughput array was scanned 
(Genechip 3000 7G scanner) and expression signals were extracted and 
normalized by applying the Robust Multichip Average (RMA) normalization 
method. A web-based probe-match tool was used to compare equine nucleotide 
sequences against individual probes on the human array, with the purpose of 
confirming that the human probe sets matched the equine query sequence of 
the corresponding gene. The data set was used to screen for novel putative 
target genes that displayed a change in expression when IL-6 stimulated 
samples were compared to their unstimulated controls. The data were only 
analysed on the gene-level and not on the exon-level. 
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4.6 Biochemical analyses (paper III) 
4.6.1 Measurement of glycosaminoglycans. 
Dimethylmethylene blue assay was used to estimate the proteoglycan content 
by quantification of sulphated GAGs (Farndale et al., 1986). Samples of 20 µl 
(cell culture media from explant cultures), standards, and controls were added 
to a 96-well microtiter plate. 100 ul of reagent solution (16 mg 
dimethylmetylene blue, 2,5 ml 99% v/v ethanol, 2 g sodium formate, 2 ml 
formic acid, 500 ml ultrapure water) was added to all wells. 
Spectrophotometric analysis was immediately performed at an absorbance 
wavelength of 530 nm. Chondroitin sulphate was used as a standard (50, 40, 
30, 20, 10, 5, 2.5 µg/ml) as well as an internal control (4, 10, 20 µg /ml); water 
was used as a blank control. All samples were analysed in duplicate and mean 
values were used for calculating ratio-to-cartilage explant wet weight. 
4.7 Protein expression analyses (papers III-IV)  
4.7.1 Proteomic analyses 
Figure 7. shows the workflow for the quantitative proteomics analysis. Tandem 
mass tags (TMTs) are small chemical molecules that covalently attach to the 
free amino termini of lysine residues, thereby labelling various peptides in a 
sample. All TMTs have the same mass but internally they are different (Figure 
8). This results in a single MS peak, but when fragmented (in MS/MS mode), 
the reporter group falls off, producing a unique reporter ion signature that can 




Figure 7. Schematic workflow for quantitative proteomics analyses of the secretome of equine 
cartilage explants. Cell culture media were harvested from control and interleukin (IL)-1β 
stimulated explants. Proteins were isolated before tryptic digestion. Tandem mass tag (TMT) 
reagents 126,127,128,129, 130 and 131 were added to the samples and mixed before liquid 
chromatography-tandem mass spectrometry (LC-MS/MS). For a quantitative comparative 
analysis of the secreted proteins from the IL-1β-stimulated and unstimulated explants, an aliquot 
from each time point was used as a reference pool. Illustration by E.Svala. 
Figure 8. Simplified structure of a tandem mass tag. The peptide-binding group covalently 
attaches to the free amino termini of lysine residues. The mass reporter consists of one of the 
following isobaric TMT reagents 126,127,128,129, 130 or 131. The mass normalizer is a balance 
group for the mass reporter, with the result that all tags have the same mass. During MS/MS 
mode the tags fragments, and subsequently the mass reporter, cleave off at the cleavable linker 
site, making relative quantification possible. Illustration by E.Svala 
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Sample preparation  
Culture media, harvested at days 3-22, (excluding days 0 and 25), were 
concentrated on 3 kDa molecular weight cut-off filters. The retentates were 
washed with water and triethyl ammonium bicarbonate until a pH value >8 was 
achieved. Sodium dodecyl sulphate (SDS) solution was added to the retentates 
and the proteins were reduced and alkylated before digestion with trypsin 
overnight at 37°C. In parallel, reference pools consisting of an aliquot from 
each sample were prepared as described above. 
Labelling of culture media with isobaric mass tags  
Samples were labeled with TMT reagents (according to the manufacturer’s 
protocol), combined and concentrated, yielding three sets of samples (see 
experimental setup in paper III). TMT-labelled peptides were separated by 
strong-cation exchange chromatography (SCX) on an ÄKTA purifier system. 
The concentrated peptides were acidified, diluted and injected onto a 
polySULFOETHYL A™ SCX column. During separation, ultraviolet 
absorbance was monitored and peptide-containing fractions were evaporated 
and desalted. 
Liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis  
The desalted and dried fractions were reconstituted and analysed on a linear 
trap quadrupole (LTQ)-Orbitrap™-Velos mass spectrometer interfaced with a 
nano-LC column constructed inhouse. The peptides were trapped on a pre-
column and separated on a reversed-phase column packed inhouse with 3-µm 
Reprosil-Pur C18-AQ particles. The LTQ-Orbitrap™ Velos was operated in 
data-dependent mode with a single MS1 fourier-transform mass-spectrometer 
precursor-ion scan. This step was followed by collision-induced and high-
energy collision dissociation MS2 scans of the five most abundant doubly or 
triply protonated ions in each precursor scan. All samples were analysed a 
second time with an exclusion list of all m/z values corresponding to peptides 
identified at 1% false discovery rate from the first MS-analysis. 
Database search and TMT quantification  
MS raw data files from all 15−20 peptides containing strong-cation exchange 
fractions within a single TMT set were merged for protein identification and 
relative quantification using Proteome Discoverer version 1.3. Database 
searches were performed using the Mascot search engine against the 
ENSEMBL horse protein and Uniref100 mammalian protein databases. For 
specific parameters see paper III. The detected protein threshold in the 
software was set to a confidence level corresponding to a false discovery rate 
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of 1% at the peptide level. TMT reporter ion intensities in MS/MS spectra were 
divided by their reference reporter ion intensities, yielding a ratio for each 
quantified peptide. A protein ratio was calculated as the median value for all 
unique peptides for a given protein. No normalisation was applied, and the 
albumin ratio was used to validate the variation in sample preparations.  
Characterization of endogenous proteolytic peptides of lubricin in synovial 
fluid  
Synovial fluid from one horse with normal articular cartilage and from one 
horse with an OCF was individually depleted from high abundant serum 
proteins by the multiple affinity removal system according to the 
manufacturer's instructions. Synovial fluid was diluted with MARS buffer A 
and injected onto the column. Absorbance was recorded at 280 nm and 
fractions with absorbance levels above background were collected. The 
collected fractions, approximately 2.5 ml each, were pooled and concentrated 
to <50 µl using 3kDa cut-off ultrafiltration. Protein separation was performed 
on NuPAGE. Following Coomassie blue staining each gel lane was cut into 15 
equally sized pieces that were individually digested by trypsin following the 
protocol previously described (Stenberg et al., 2013). Each fraction was 
individually analyzed by nanoLC-MS/MS on an Ultimate 3000 separation unit 
coupled in-line to an QExactive mass spectrometer. The resulting data files 
were merged into two data sets representing the two horses. The proteins were 
identified by performing searches using the parameters described in detail in 
paper IV. 
 
4.7.2 Western Blot  
COMP 
For COMP detection, aliquots (12 µl) of each medium harvested between days 
0−25 from explants originating from a single horse, were mixed with 
electrophoresis buffer (0.125 M Tris-HCl, 2% w/v SDS, 0.002% w/v 
bromophenol blue, 20% v/v glycerol) in the absence of 2-mercaptoethanol. The 
samples were applied to a 4-20% w/v SDS-polyacrylamide gel (PAGE) and 
run according to the Laemmli protocol (Laemmli, 1970). After electrophoresis, 
the proteins were electrotransferred onto a nitrocellulose membrane in Tris-
glycine buffer (25 mM Tris-HCl, 192 mM glycine, pH 8.3, 20% v/v methanol) 
at 120 V for 2 h. Following the transfer, the membranes were blocked with 5% 
w/v skimmed milk in Tris-buffered saline pH 7.4 with 0.05% v/v Tween 20 
(TBS/T). Antigenic COMP was detected with an anti-bovine polyclonal 
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antibody (1:2000, kindly provided by Professor Dick Heinegård) in 5% w/v 
skimmed milk in TBS/T. Membranes were washed with TBS/T prior to 
incubation with the secondary antibody, goat anti-rabbit IgG-HRP. 
Immunoreactive bands were detected using chemiluminescence detection 
reagents. 
Lubricin 
For lubricin detection, 20 µl of collected medium was separated by gradient 
SDS-AgPAGE after reduction with 10 mM dithiothreitol and alkylation with 
25 mM iodoacetamide. Proteins were blotted onto a PVDF membrane using a 
semi-dry method, as previously described (Schulz et al., 2002). After blocking 
with 1% w/v BSA in TBS/T, horse lubricin was detected with monoclonal 
mouse anti-human lubricin and HRP-conjugated rabbit anti-mouse 
immunogoblulins. After washing, immobilized antibodies were visualized by 
an ultrasensitive enhanced chemiluminescent substrate for low-femtogram-
level detection. 
4.7.3 ELISAs 
Chondroitin sulphate 846 (CS846)  
To monitor aggrecan synthesis, a commercially available ELISA assay was 
used for the detection of CS846 in culture media from pellets (stimulated and 
unstimulated). The antibody has a strong cross-reactivity for horse. The assay 
was performed according to the manufacturer’s protocol, although cell culture 
medium was used instead of serum. Analyses were performed on duplicate 
samples (diluted 1:300) and the lower detection limit was 20 ng/ml.  
MMP-13 
A commercially available ELISA assay was used for the detection of active 
MMP-13 in culture media from pellets and explants (stimulated and 
unstimulated). Culture medium was diluted 1:10 for pellets and 1:50-1:100 for 
explants. Adding p-aminophenylmercuric acetate (APMA) to the samples 
activated the pro-forms (by removal of the C-terminal domain) but not the 
latent or mature forms bound to their inhibitors, TIMPs. The assay was 
performed according to the manufacturer’s protocol. Analyses were performed 
on duplicate samples and the lower detection limit was 8 pg/ml. 
C1, 2C  
A commercially available ELISA assay was used for the detection of the 
carboxy terminus neoepitope of the ¾ piece (C1, 2C) (Billinghurst et al., 2000; 
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Billinghurst et al., 1997). This piece is generated by the cleavages of type I and 
type II collagen by collagenases. The antibodies in the assay, which have a 
strong cross-reactivity with horse, recognize an α-chain fragment containing an 
approximately 8-amino acid sequence on the carboxy terminus of the ¾ length 
piece. This fragment is produced by collagenase (MMP-1, MMP-8 and MMP-
13) cleavage of type II collagen. These antibodies show affinity for similarly 
cleaved human type I collagen α-chains. The assay was performed according to 
the manufacturer’s protocol, except that cell culture medium was used instead 
of serum. Analyses were performed on duplicate samples of culture medium 
from explants (diluted 1:2 or 1:4) and the lower detection limit was 10 µg/ml. 
Lubricin 
25 µL of synovial fluid or cell culture media from explants were coated on 96-
well microtiter plates in 0.1 M sodium carbonate buffer, pH 9.5. After washing 
and blocking with 1% w/v BSA in TBS-T buffer, bound lubricin was detected 
by mAb13 and HRP-conjugated rabbit anti-mouse immunoglobulins. 
Tetramethyl benzidine buffer was used as substrate for 20 min before a stop 
solution was added (1M H2SO4). Color development was measurement at 450 
nm. 
4.8 Glycomic analysis  
Acidic proteins in horse synovial fluids were purified as previously described 
for the human acidic proteins (Jin et al., 2012). Reduced and alkylated acidic 
proteins were separated by SDS-agarose polyacrylamide composite gel 
(AgPAGE) and blotted onto a polyvinylidene fluoride (PVDF) membrane. 
Alcian blue-stained protein bands, corresponding to the size of lubricin, were 
excised and subjected to reductive β-elimination. Released O-linked 
oligosaccharides were desalted and dried for capillary graphitized-carbon LC-
MS and LC-MS/MS in negative-ion mode using an LTQ Ion Trap (Jin et al., 
2012; Schulz et al., 2002). Oligosaccharides were identified from their MS2 




All statistical analyses were performed with software; values of P < 0.05 were 
considered significant. 
In paper I, the statistical model ANOVA was used to analyze the difference 
in chondrocyte pellet gene expression as well as the concentrations of MMP-13 
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and CS846 in the culture medium. The statistical model included the fixed 
effects of animal, site, stimulation, and interactions between site and 
stimulation. Pairwise comparison of least square means between sites and 
between cytokine-stimulated and untreated pellets was tested for significance. 
In paper II, least square mean data were analysed by means of 2-way 
ANOVA with the variables time, stimulation, and the interaction between time 
and stimulation included in the model. Time was considered as a categorical 
variable to determine the stimulation time that would be important for changes 
in GDF-5 mRNA expression. Significant variables identified in the 2-way 
ANOVA were analysed with a multiple-comparisons procedure (Holm-Sidak 
method) to further identify the groups with significant differences within the 
variable. To evaluate the effect of cytokine stimulation, logarithmic gene 
expression values for 1- to 2-h (short-term) and 12- to 48-h (long-term) 
stimulations were compared with values for unstimulated chondrocytes using a 
pairwise t-test. Due to the low transcriptional effect and the limited number of 
animals, statistical tests were not performed for the microarray analyses in 
paper II. 
For paper III no statistical analyses was performed due to the limited 
number of animals in the study. 
In paper IV, all quantitative data from the glycomic analysis of synovial 
fluid were presented as mean± standard deviation (SD). Two-way ANOVA 
(multiple comparisons) were performed to compare synovial fluid from normal 
joints and joints with OA or OCF.  
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5 Results 
A summary of the main results follows; please see the individual papers for 
details. 
5.1 Paper I 
The effects of cytokine stimulation (IL-1β, IL-6 and HMGB-1) on chondrocyte 
metabolism in chondrocyte pellets were evaluated with gene expression 
analyses, ELISA assays, and immunohistochemistry. For the chondrocyte 
pellet culture, chondrocytes from either the noncontact area of the less-loaded 
PC or the high-loaded area of DRF were used to evaluate the effect of gene 
expression in anatomical sites exposed to different loading in vivo.  
There was a significant increase in mRNA gene expression of versican 
(P<0.0001), MMP-9 (P=0.0137) and TIMP-1 (P=0.0059) in response to IL-1β 
stimulation compared to unstimulated controls. In contrast, there was a 
significant decrease in aggrecan (P<0.0001), collagen type I (P=0.0077), and 
collagen type II (P=0.0082) gene expression in the IL-1β stimulated 
chondrocyte pellets compared to unstimulated controls. MMP-13 and 
ADAMTS-5 gene expressions were also clearly increased in IL-1β-stimulated 
pellets, but since the residual was not normally distributed, a test of 
significance was not performed. A trend towards decreased COMP expression 
(P=0.0543) was also detected. Response to cytokines rarely differed between 
DRF and PC chondrocyte pellets. 
Additionally, IL-1β stimulated pellets resulted in a decreased safranin O 
staining and an increased COMP immunostaining. Media from IL-1β-
stimulated pellets showed the lowest concentrations of aggrecan epitope CS 
846; however, the results were not statistically significant. Concentrations of 
active MMP-13 were markedly increased from 0.28 ng/ml in control media, to 
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62.5 ng/ml in IL-1β-stimulated pellets from DRF; the value in the control 
medium was 0.03 ng/ml and 53.4 ng/ml in IL-1β-stimulated pellets from PC.  
The effects of IL-6 and HMGB-1 on gene expression varied in different 
horses. There was an indication of a slight anabolic effect due to the 
upregulatory effect on SOX-9, which was seen by both cytokines, but it was 
only statistically significant for HMGB-1-stimulation (P=0.0120). The COMP 
immunostaining and safranin O staining, in IL-6- and HMGB-1-stimulated 
pellets, were similar to the staining in the control. 
A notable difference was seen between the unstimulated chondrocyte 
pellets of DRF and PC in the three youngest horses (1-, -2 and 3-years old). A 
relatively higher expression of SOX-9, aggrecan, and collagen type II was 
evident in the PC, which is a less-loaded area in vivo compared to the highly-
loaded area of DRF. There was a higher versican and collagen type I gene 
expression found in DRF compared to PC.  
 
5.2 Paper II 
The presence of GDF-5 in normal articular cartilage and OCFs was evaluated 
with immunohistochemistry. The effects of cytokine stimulation (IL-1β and IL-
6) on chondrocyte pellets were evaluated with immunohistochemistry and gene 
expression analyses. 
Macroscopically normal articular cartilage showed prominent cellular and 
pericellular staining of GDF-5 in the superficial and upper-third of the middle 
zones of the articular cartilage. GDF-5 expression was localized to the 
chondrocytes and their pericellular matrix in the middle and deep parts of the 
articular cartilage from the OCF samples.  
Significantly (P = 0.041) lower gene expression of GDF-5 was detected in 
IL-1β stimulated pellets compared to the unstimulated chondrocyte pellets. 
Furthermore, a significant (P = 0.002) difference was detected in mean GDF-5 
expression between chondrocyte pellets stimulated with IL-1β and those 
stimulated with IL-6, with the higher expression being in the IL-6-stimulated 
chondrocyte pellets.  
When analyzing the effect of cytokine stimulation at the individual time 
points, IL-6 stimulation for 2 h showed a significant (P = 0.007) upregulation 
of GDF-5 mRNA expression versus unstimulated chondrocyte pellets. 
Significance was also found between IL-6 stimulated and IL-1β stimulated 
chondrocyte pellets at 48 h, with a higher expression in the IL-6 group (P = 
0.011).  
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The global transcriptional analysis (microarray) for chondrocyte pellets 
stimulated with or without IL-6 for 1h or 2 h, identified 59 and 21 genes, 
respectively, regulated by IL-6 (mean fold change in expression > 1.5). 
IL-6 stimulation resulted in an induction of gene expression for a negative 
regulator of the canonical Wnt-signalling pathway, called CCDC88C, after 1 h 
of stimulation. A screen of the genes in the canonical Wnt-signalling pathway 
identified 23 affected genes in the IL-6 stimulated pellets compared to controls. 
IL-6 stimulation resulted in an increase of several inhibitors and negative 
regulators of the canonical Wnt-signalling pathway and a decreased expression 
of receptor and ligands (summarized in figure 9).  
 
Figure 9. Illustration showing a summary of the results from the microarray analysis of genes in 
the canonical Wnt pathway, based on their known function in combination with the altered gene 
expression by IL-6 stimulation (1, 2 h) in paper II. The regulated expression of genes by IL-6 
marked red leads to an inhibited canonical pathway while genes marked green leads to an 
activation of the canonical Wnt pathway. As an example, DKK1, which is an extracellular 
negative regulator of the canonical pathway, was downregulated by IL-6 at 1 h, indicating an 
activation of the pathway, and therefore marked green. The key activator, β-catenin, was 
downregulated at 2h by IL-6, indicating an inhibited pathway, therefore marked red.        
llustration by Anna Thorfve. 
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Immunohistochemistry was used to evaluate the expression of nuclear 
dephosphorylated β-catenin and GSK3β in chondrocyte pellets stimulated with 
IL-6 or IL-1β (for 1 h). Results showed prominent nuclear dephosphorylated β-
catenin staining in chondrocyte pellets stimulated with IL-1β, but only a few 
cells stained for β-catenin in chondrocyte pellets stimulated with IL-6. This 
result was similar to findings for unstimulated chondrocyte pellets. Cellular 
immunostaining of GSK3β  was detected in a diffuse pattern in IL-6-stimulated 
chondrocyte pellets; only a few cells had GSK3β  staining in IL-β-stimulated 
chondrocyte pellets, again similar to findings for unstimulated chondrocyte 
pellets. The results suggest that the inhibition of the canonical Wnt-signalling 
pathway is caused by IL-6. 
5.3 Paper III 
The secretome of equine articular cartilage explants cultured in the presence or 
absence IL-1β was studied with quantitative proteomics, ELISA assays, and 
Western Blot during three-day intervals for a total of 25 days.  
The content of GAG was highest at day 3 in media from both stimulated 
and unstimulated cartilage explants. The concentration was higher (1.5-2.9 
times) in the medium from IL-1β stimulated cartilage explants at all time 
points except at day 15 where it had the same concentration as the control. 
Intact COMP was observed by Western Blot analysis in media from 
unstimulated cartilage explants at each time point, while five distinct bands 
(correlated to the calculated mass of monomeric to pentameric COMP) were 
observed at each time point in the media from IL-1β-stimulated cartilage 
explants. 
The concentration of C1, 2C peptide in media from IL-1β-stimulated 
cartilage explants increased from day 15 to day 25 (4.1 µg/ml) whereas in the 
unstimulated cartilage explants, it was low throughout the culture period 
(highest concentration 0.04 µg/ml). The concentration of activated MMP-13 
was first detected at day 3 (544 ng/ml) in media from IL-1β-stimulated 
cartilage explants.  Concentrations during the culturing period remained high 
until a distinguished decrease on day 22. Very low concentrations of active 
MMP-13 were detected in media from unstimulated cartilage explants; the 
highest concentration was detected at day 22 (100 ng/ml).  
The quantitative proteomics identified a total of 126 proteins in media. IL-
1β stimulation resulted in an abundance of proteins related to inflammation, 
including MMP-1, -3, -13 which were higher in media from IL-1β-stimulated 
than unstimulated cartilage explants at any given time point. Acute phase 
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proteins (SAA), complement components (complement C1s, complement 
factor C1r, complement factor B), and IL-6 were also identified.  
A time-dependent degradation of the molecular components of the ECM 
was evident in media from cartilage explants stimulated with IL-1β (Figure 
10). ECM molecules were released at different time points, with a high levels 
in IL-1β-stimulated cartilage explants at days 3-6 for aggrecan, COMP, 
chondroadherin, osteomodulin, lubricin (proteoglycan-4), PCOLCE, 
hyaluronan and proteoglycan link protein-1, lumican, thrombospondin-1, 
epiphycan, and collagen type XI-α1. A semitryptic peptide originating from the 
G1 and G2 region of aggrecan was identified close to the previously described 
MMP cleavage site PEN↓FFG, supporting endogenous processing.  
High levels of ECM molecules from IL-1β-stimulated cartilage explants at 
day 9-12 were found for collagen type XII, XI-α2 and at days 15-22 for 
collagen type-II, -VI, -IX, fibronectin, biglycan, CILP, fibromodulin and 
decorin. Lumican, fibronectin, CILP, fibromodulin, and decorin displayed a 
diphasic release in the media from IL-1β-stimulated cartilage explants, with 
two peak levels at early (days 3 and 6) and late (day 22) time points. 
The procollagen type II C-terminal propeptide was identified as a 
semitryptic peptide in markedly higher levels in media from unstimulated 
explants than in the media from IL-1β-stimulated explants. A high level of 
procollagen C endopeptidase enhancer (PCOLCE) — a glycoprotein that binds 
to newly synthesised procollagen molecules and catalyzes the enzymatic 




Figure 10. Time-dependent release of ECM molecules from cartilage explants into the medium. 
The pro-inflammatory cytokine IL-1β was used to induce degradation of equine articular cartilage 
explants in vitro with the purpose of mimicking OA in vivo. The release of ECM related proteins 
at different time points was detected with quantitative proteomics. Fragmentation of aggrecan and 
COMP was detected already at days 3-6 while the degradation of the collagen network was 
observed at days 18-22, similar to OA progression in vivo. At the end of the culture period, 
depletion of GAGs was seen in the IL-1β stimulated explant (safranin O staining). Histological 
pictures by Maria Löfgren. Illustration by E.Svala.  
5.4 Paper IV 
The secretion and glycosylation pattern of lubricin in synovial fluid from joints 
with normal articular cartilage, with structural OA lesions and with OCF, was 
studied with proteomics, glycomics, and Western Blot. Lubricin levels in 
media and extract of cartilage explants stimulated with or without IL-1β were 
also studied with quantitative proteomics, ELISA assays, and Western Blot. 
Both core 1 [Galβ1-3GalNAcol] and 2 O-glycans [Galβ1-3(GlcNAcβ1-
6)GalNAcol] were identified on equine synovial lubricin; however, core 1 O-
glycans were predominant in all purified lubricin (synovial fluids from joints 




Figure 11. O-glycan profiles of equine synovial lubricin isolated from equine joints with normal 
articular cartilage, osteochondral fractures, and structural OA lesions. All observed mass was 
indicated as [M-nH]n-. 10-15% of core 1 O-glycans were neutral O-glycans (m/z 384) while more 
than half of core 1 O-glycans were mono-sialylated (m/z 675 and 691) and 20-30% of core 1 O-
glycans were disialylated (m/z 966 and 982). Less than 10% of total O-glycan was core 2 O-
glycans. All of them were sialylated with disialylated as predominant structures (m/z 1331, 7052- 
and 8472-) and monolylated as minor ones (m/z 1040). One sulphated O-glycan (m/z 7052-) was 
detected in both normal and OCF samples. O-glycan structures are depicted using Consortium for 
Functional Glycomics (CGF) symbol nomenclature. Symbol represents: yellow circle, galactose; 
yellow square, N-acetyl galactosamine; blue square, N-acetyl glucosamine; purple diamond, N-
acetyl neuraminic acid; shallow purple diamond, N-glycolyl neuraminic acid.  
Illustration by Chunsheng Jin. 
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The majority of core 1 O-glycans were sialylated (mainly Neu5Ac and less 
extent of Neu5Gc), and the most common form was mono-sialylated core 1 O-
glycans (60% of all core 1 O-glycans), followed by di-sialylated (20-30%) and 
neutral (10%) core 1 O-glycans. Mono-sialylated core 1 O-glycans consist of 
two type O-glycans, Neu5Ac(Gc)α2-3Galβ1-3GalNAcol (linear structure; m/z 
675 and 691 in Figure 11) and Galβ1-3(Neu5Acα2-6)GalNAcol (branched 
structure; m/z 675 in Figure 11). The linear is predominant in a range of 51-
59% (of all O-glycan); branched, however, is minor only in a range of 1-3%.   
Significant differences were found for the mono-sialylated core 1 O-glycans 
from the synovial fluid of normal joints compared to that of joints with OA 
(P=0.0283) or OCFs (P=0.001); the lower amount in synovial fluid came from 
the normal joints. Moreover, significant differences were found for the di-
sialylated core 1 O-glycans [Neu5Ac(Gc)α2-3Galβ1-3(Neu5Acα2-
6)GalNAcol; m/z 966 and 982 in Figure 11] in synovial fluid from normal 
joints compared to that of joints with OCFs (P=0.0297), with the higher level 
in synovial fluid coming from the normal joints. 
The highest level of lubricin was detected with quantitative proteomics 
analysis and ELISA at day 3 in media from both IL-1β stimulated and 
unstimulated cartilage explants; nevertheless, the level of lubricin was higher 
in media from IL-1β stimulated cartilage.  
Western Blot analysis confirmed the presence of lubricin in media from IL-
1β stimulated cartilage explants, at all time points, but with a faint staining at 
day 22. Media from unstimulated cartilage explants, however, revealed the 
presence of lubricin only at days 0, 3 and 6. The Western Blot analysis of 
extraction from the unstimulated and stimulated cartilage explants showed no 
lubricin.  
The proteomic analysis for non-tryptic cleavage sites identified 17 cleavage 
sites at the C-terminal sequence in synovial fluid from one horse with normal 
articular cartilage and from one horse with OCF. These sequences were 
compared to those identified in media from cartilage explants. One identical C-
terminal non-tryptic cleavage site at position LRPH|VLTP was identified in 
synovial fluids and media from both IL-1β-stimulated explants and control 






Figure 12. Lubricin acts as a boundary lubricant in articular cartilage present in synovial fluid and 
superficial zone of cartilage. Lubricin is secreted by the chondrocytes and cells in the meniscus 
into the superficial zone of articular cartilage, or by synoviocytes in synovium into synovial fluid. 
Lubricin consists of somatomedin B-like-domains (SMB) at the N-terminus, followed by a 
mucin-like domain that is heavily glycosylated and ends with a hemopexin-domain (Pex) at the 
C-terminus (Rhee et al., 2005b). In paper IV we demonstrated an identical proteolytic cleavage 
site in both in vivo (synovial fluid) and in vitro (media from IL-1β-stimulated and from control 
cartilage explants). The cleavage site LRPH|VLTP was identified in the C-terminal end of 
lubricin.  Illustration by E. Svala. 
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6 General discussion  
 
6.1 In vitro methods: chondrocyte pellets and cartilage explants 
To study in vitro articular cartilage that resembles the chondrocytes of the in 
vivo articular cartilage, 3D cell-culture pellets (Tallheden et al., 2004) were 
used. However, when the chondrocytes expand in monolayer, they de-
differentiate into a fibroblast-like phenotype (von der Mark et al., 1977). In this 
phenotype there is a gene downregulation of cartilage specific markers such as 
collagen type II, SOX-9 and aggrecan, and an upregulation of RUNX, MMP-
13, ALP, and OPN, these being associated with a hypertrophic phenotype 
(Caron et al., 2012). In in vitro 3D cell-culture pellets (Ma et al., 2013; 
Tallheden et al., 2004), chondrocytes are re-differentiated. This results in a 
gene upregulation of cartilage specific markers such as collagen type II, SOX-
9, and aggrecan, and a down regulation of the hypertrophic markers such as 
collagen type X (Caron et al., 2012), rendering the pellets with a chondrogenic 
phenotype. The studies in papers I and II established pellets of equine 
chondrocytes and further developed and validated the in vitro system as a high 
throughput approach. Replacement of 15-ml tubes with 96-well plates 
facilitated the culturing of large amount of chondrocyte pellets.  
However, culturing cartilage explants with the intact tissue comprising 
chondrocytes and its ECM will provide an even more in vivo like model of the 
articular cartilage tissue, compared to chondrocyte pellet cultures. The 
chondrocytes in cartilage explants display intact chondrogenic features, instead 
of going through the de-differentiation and subsequent re-differentiation that 
occur in chondrocyte pellets (Moo et al., 2011). Hence, articular cartilage 
explants, cultured in vitro, were used (papers III and IV) to study the release 
and degradation pattern of the ECM.  
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The use of in vitro experiments aims to mimic the in vivo situation; 
nevertheless in vitro experiments have many limitations. OA involves all the 
structures of the joint (including bone, ligaments and synovial tissues). 
Because the microenvironment (including mechanical load and the cross-talk 
between tissues during the initiation and progression of OA) is important, co-
cultures of tissues in the joint could improve the system by mimicking the in 
vivo situation of OA. The induction of inflammation by addition of IL-1β in 
cell culture media could also be improved by using biomaterials that provide a 
constant release of cytokines over time (Murab et al., 2013). This would more 
closely resemble the pathological condition in vivo.   
Nevertheless, the results from in vitro studies of inflamed articular cartilage 
can render important and novel findings regarding the ECM molecule release 
and fragmentation that is only present in diseased cartilage. Fragments of ECM 
molecules can be evaluated as potential biomarkers of early OA and for 
monitoring the progression of OA in vivo. 
 
6.2 Effects of the cytokines IL-1β, IL-6 and HMHB-1 on 
chondrocyte pellets in vitro (papers I and II) 
The effect of cytokine stimulation on gene and protein expression of molecules 
related to the ECM metabolism was studied (paper I). Gene expression (an 
increase in versican, MMP-9, -13, ADAMTS-5 and a decrease in aggrecan and 
collagen type II) and protein analyses (decreased glycosaminoglycan content, 
increased MMP-13 activity and decreased aggrecan synthesis) demonstrated a 
catabolic effect of IL-1β stimulation on cartilage metabolism. These results 
confirm those of other studies on IL-1β-stimulated equine cartilage (Neil et al., 
2005; Richardson & Dodge, 2000). Additionally, SOX-9 gene expression was 
reduced by IL-1β stimulation, suggesting an anti-chondrogenic effect, since 
SOX-9 is required for chondrocyte differentiation and in chondrogenesis (Bi et 
al., 1999). The effects of IL-6 and HMGB-1 on equine cartilage metabolism in 
vitro were variable; inter-individual differences had no major effect on ECM 
degradation, and caused only minor alterations in the gene expression of 
MMPs and ADAMTs. In contrast, an upregulation of SOX-9 was observed for 
both IL-6 and HMGB-1. The HMGB-1 stimulation was statistically significant, 
indicating a mild anabolic effect. 
The response to these cytokines (IL-1β, IL-6 and HMGB-1) was also 
evaluated, using chondrocytes harvested from two different anatomical areas of 
the carpal bone–the less-loaded (PC) area and the highly loaded area (DRF) of 
C3 (Palmer et al., 1994). The highly loaded DRF is more prone to develop 
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cartilage lesions compatible with OA (Pool & Meagher, 1990); it has been 
suggested that the effect of IL-1β differs in topographically defined regions in 
human OA joints (Barakat et al., 2002). However, our results showed that 
chondrocytes harvested from DRF and PC responded in a similar manner to 
cytokine stimulation. Our results are supported by another study of cytokine-
stimulated equine cartilage (Little et al., 2005), suggesting that site-associated 
cartilage destruction in equine carpal OA is not explainable by topographical 
differences in the response to inflammatory mediators. Some site-associated 
changes were, however, found in the youngest horses, for certain genes, which 
might be explained by an age-related cell response (Morris & Treadwell, 
1994).  
Furthermore the results suggested a more hyaline cartilage phenotype of 
unstimulated cells harvested from the less loaded area of PC, with higher Sox9, 
aggrecan, and collagen type II gene expression compared to the highly loaded 
area of DRF. However higher versican and collagen type I gene expression, 
suggesting a more fibrocartilaginous gene profile was found in DRF compared 
to PC. This topographical difference in the articular cartilage phenotype in the 
young horses may indicate an altered metabolism, after frequent mechanical 
load. A topographic variation in proteoglycan synthesis in articular cartilage 
from sheep has been related to mechanical stress (Little et al., 1996). There is 
significantly less proteoglycan synthesis in regions of high mechanical load 
(Little et al., 1996) and the variation in chondrocyte metabolism is suggested to 
be determined by post-natal loading (Little & Ghosh, 1997). 
GDF-5, also known as bone morphogenetic protein-14, is one of the earliest 
known markers for joint formation (Storm & Kingsley, 1996). It is an essential 
protein in chondrogenesis, chondrocyte proliferation, appendicular skeletal 
patterning, and longitudinal bone growth (Settle et al., 2003). Mutations in the 
GDF-5 gene result in abnormal joint development and skeletal malformation 
diseases (Hellman et al., 2012). An association between a functional 
polymorphism (T/C; rs143383) in the 5′-untranslated region of GDF5 and 
susceptibility to OA has been confirmed in European as well as Asian 
population studies, suggesting that reduced GDF-5 expression is involved in 
the pathogenesis of knee and hip OA (Chapman et al., 2008; Miyamoto et al., 
2007). The catabolic effect after IL-1β stimulation of chondrocyte pellets, 
(paper I), was further supported by the down regulation of GDF-5 mRNA 
expression (paper II). Similar findings of regulation of GDF-5 by IL-1β-
stimulation have been reported in human chondrocytes cultured in monolayer 
(Liu et al., 2010) and in 3D cultures of human intervertebral annulus cells 
(Gruber et al., 2014).  
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IL-6 is a regulatory or modulatory mediator in OA (van der Kraan & van 
den Berg, 2000; Goldring, 1999), but also crucial for IL-1β-induced matrix 
degradation (Westacott & Sharif, 1996). It was found to upregulate the gene 
expression of GDF-5 within 2 hours after stimulation of chondrocyte pellets 
(paper II). This is in line with the trend of an upregulation of SOX-9 gene 
expression after 48 hours of stimulation (paper I), suggesting a 
prochondrogenic effect by IL-6. IL-6 stimulation of human chondrocytes in 
vitro increases the production of GAGs (Tsuchida et al., 2012) and expression 
of collagen type II, BMP-7, BMP receptors (Namba et al., 2007) and TIMP-1 
(Silacci et al., 1998). Using a global microarray analysis, we further studied the 
short-term effect of IL-6, in order to investigate by which mechanisms and 
pathways IL-6 exerts its effects. One pathway affected by the IL-6 stimulation 
of chondrocyte pellets, is the canonical Wnt-signalling pathway, which has an 
essential role in embryonic joint specification, formation and chondrogenesis; 
it is also associated with OA pathogenesis (Corr, 2008). Upon binding of 
extracellular Wnt ligands to receptors (Frizzled) and co-receptors (LRP 5/6), 
the key protein β-catenin is translocated into the nucleus, while in the absence 
of Wnt ligands, β-catenin is phosphorylated by GSK3β and subjected to 
proteosomal degradation. Nuclear translocation of β-catenin is a sign of 
activation of the canonical Wnt-signalling pathway (Willert & Nusse, 1998). 
Active canonical Wnt-signalling maintains chondroprogenitor cells in a 
proliferative state, inhibiting their development into mature chondrocytes 
(Tamamura et al., 2005). In contrast, activation of β-catenin in articular 
chondrocytes induces hypertrophy, expression of ECM degradation proteins, 
and stimulates matrix mineralization (Enomoto-Iwamoto et al., 2002; Ryu et 
al., 2002). Activation of β-catenin signalling leads to an OA-phenotype in 
mice, with cell cloning, surface fibrillation, vertical clefting, osteophyte 
formation and reduced articular cartilage area (Zhu et al., 2009). 
 After IL-6 simulation, the inhibitors CCDC88C, GSK3β and Wnt inhibitory 
factor 1 were upregulated (paper II). Furthermore there was an increased 
expression of genes involved in the ubiquitin-mediated degradation of β-
catenin and an indication of down regulation of β-catenin. Together with the 
decreased expression of ligands (WNT8B, WNT9B) and receptors (FZD8) 
belonging to the canonical Wnt signalling pathway, this suggests an inhibitory 
effect by IL-6. These results were supported by the immunohistochemistry 
staining of GSK3β and β-catenin in the chondrocyte pellets. The IL-1β-
stimulated chondrocyte pellets displayed nuclear β-catenin, a clear sign of 
Wnt-signalling activity. In contrast, GSK3β, which phosphorylates β-catenin, 
was clearly present in the IL-6 stimulated chondrocyte pellets.  
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GDF-5 stimulation of human chondrocytes has been shown to inhibit the 
canonical Wnt-signalling pathway by increased gene expression of the 
inhibitors DKK1 and FRZB (Enochson et al., 2014). A possible explanation for 
the upregulation of SMAD4 and GDF-5 (and consequent downregulation of the 
canonical Wnt pathway) by IL-6 (paper II) could be due to cross-talk between 
the two pathways (Hiyama et al., 2011). This would further strengthen the role 
of IL-6 as a regulatory cytokine with possible prochondrogenic effects. Taken 
together the data from paper II suggest that IL-6 inhibits the canonical Wnt-
signalling pathway in chondrocyte pellets.  
6.3 Effects of IL-1β stimulation on the secretome of articular 
cartilage explants cultured in vitro (paper III) 
Previous studies (Williams et al., 2013; Clutterbuck et al., 2011) have explored 
the secretome of equine articular cartilage from the MCP joint. However our 
results are the first describing a time-dependent, relative quantification of 
equine ECM proteins in an in vitro inflammation model.  
In order to develop diagnostic tools and an evaluation of treatments for OA, 
it is necessary to elucidate the exact series of events with the specific 
fragmentation patterns of ECM and the enzymes responsible for the 
degradation of articular cartilage. An approach used to find potential 
biomarkers of various diseases, including OA, is high-resolution proteomic 
analyses by mass spectrometry (Stenberg et al., 2013; Takinami et al., 2013; 
Ruiz-Romero & Blanco, 2010). LC-MS/MS, a highly specific and sensitive 
technique, is used not only in basic research but also in routine laboratory 
diagnosis such as drug monitoring and endocrinology/metabolism applications 
(Leung & Fong, 2014). In studies III and IV we used quantitative proteomics to 
study the secretome of equine articular cartilage explants over time after IL-1β 
stimulation. 
The explants were harvested by cutting, which consequently initiates an 
inflammation (Gruber et al., 2004). Thus, the first release of ECM proteins 
from unstimulated explants into the medium could be explained by the 
inflammation caused by harvest of the cartilage and the effect of long-term 
culturing. However, the unstimulated explant recovers from this inflammation 
with a release of COMP (proteomics) and also native COMP (Western Blot). 
Additionally, at days 3-6, we detected high levels of procollagen type II C-pro 
peptides, PCOLCE, and PCOLCE2, suggesting a type II collagen synthesis.  
At the same time, there was little or no evidence of MMPs. This suggests that 
the quantitative proteomics results in the medium from the unstimulated 
explant represent both newly synthesized molecules and degradation.  
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In the IL-1β stimulated explants, the degradation process continued 
throughout the period. Numerous in vitro studies of IL-1 stimulated articular 
cartilage explants show a time-dependent pattern in both the release and 
degradation of ECM, starting with aggrecan, followed by COMP, fibromodulin 
and finally collagen type II, with complete dissolution of the collagen network 
(Williams et al., 2013; Heinegård, 2009; Heathfield et al., 2004; Dickinson et 
al., 2003; Sztrolovics et al., 1999). Our results were in agreement with these 
findings and also revealed a release pattern for other ECM proteins in equine 
cartilage. Media from IL-1β-stimulated explants showed a high concentration 
of active MMP-13 during the entire culture period, similar to what is seen in 
OA cartilage (Goldring et al., 2011). The high levels of MMP-1, -3 and -13 
and lack of ADAMTs during the in vitro culture are also reported by other 
studies of cytokine-stimulated equine articular cartilage (Williams et al., 2013; 
Clutterbuck et al., 2009).  
IL-1β significantly upregulates the mRNA gene expression of IL-6 in 
equine chondrocytes (David et al., 2007) and we detected high levels of IL-6 in 
the media from IL-1β stimulated explants. Moreover, other mediators of 
inflammation were detected, such as serum amyloid A (which may play may a 
key role in inflammatory process in OA (de Seny et al., 2013)) and chemokine 
(C-C motif) ligand 20, an important chemokine in RA (Kawashiri et al., 2009). 
Complement components, involved in the initial stages of the activation of the 
classical (C1r, C1s) and the alternative (CFB) pathway, increased in the media 
from IL-1β stimulated explants, consistent with a study of IL-1β-stimulated 
bovine cartilage explants (Stevens et al., 2008). Deregulation of the 
complement system has a key role in the pathogenesis of OA; the expression 
and activation of complement is high in human OA joints and the membrane 
attack complex is crucial to the development of OA in mice models (Wang et 
al., 2011). COMP fragments can activate the alternative pathway (Happonen et 
al., 2012), while SLRPs (fibromodulin, osteoadherin, and chondroadherin) can 
activate the classical pathway (Sjoberg et al., 2009). This implies that there is 
an inflammation-related release of ECM molecules linked to the regulation of 
complement components. The SLRPs interact with collagens to form a proper 
ECM network (Kalamajski & Oldberg, 2010); their biphasic release (early and 
late stage of culturing) may reflect increased synthesis and release of the 
protein, in intact or fragmented form. 
The degradation of the collagen network progressed in a time-dependent 
pattern, with release of collagen types -XII, -IX, -VI and type II. A high level 
of collagen type XII was detected in media from IL-1β-stimulated explants, at 
day 9-12, before the release of collagen types -IX, -VI and –II. Collagen type 
XII is involved in the organization of collagen fibrils in developing rat 
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cartilage (Gregory et al., 2001) and competes or collaborates with SLRPs 
(Eyre, 2002). The NC4 domain of Collagen IX is the segment of the molecule 
that projects out from the fibril surface, connecting to ECM molecules while 
the C-terminal part can interact with other collagens. Peptides originating from 
the NC4 domain were identified in media from IL-1β-stimulated explants at 
days 15-18 but no peptides were identified from the C-terminal part of 
Collagen IX. This suggests that the NC4 domain was cleaved by proteolytic 
enzymes, resulting in a loss of collagen type IX from type II fibrils as the 
initial step of destruction of the fibrillar network. Increased release of collagen 
type VI, which supports the collagen network, was found at day 18, preceding 
the peak levels of SLRPs in media from IL-1β-stimulated explants. Collagen 
type II release was highest at the end of the culturing period (day 22) and 
collagen degradation was identified by C1, 2C (ELISA), in agreement with 
late-stage OA (Goldring & Otero, 2011). The low levels of procollagen type II 
C-propeptide, a product of endogenous proteolytic processing of newly 
synthesised proprotein, in the media from the stimulated explants suggest that 
collagen type II synthesis was not prominent. 
6.4 Presence of GDF-5 in normal articular cartilage and OCFs 
(paper II) 
The presence of GDF-5 in human articular cartilage has been found in all 
cartilage zones (Bobinac et al., 2008) but also restricted to the upper zones 
(Erlacher et al., 1998). Our results are in agreement with the latter observation, 
with the localization of GDF-5 restricted to the superficial and middle zones of 
normal equine articular cartilage. The presence of chondrocytes, positive for 
GDF-5 in the superficial zone, coincides with the presence of progenitor cells 
in this area in normal equine (McCarthy et al., 2012) and human (Dowthwaite 
et al., 2004) cartilage. The GDF-5 positive chondrocytes, in the OCFs, were 
localized in most zones of the articular cartilage. Previous studies have shown 
that chondrocytes from equine OCFs synthesize COMP (Skiöldebrand et al., 
2005), collagen type II (Frisbie et al., 1999), and express IL-6 (Ley et al., 
2009; Ley et al., 2007). These results, taken together with the presence of 
GDF-5, indicate an anabolic process in the cartilage of the OCFs, maybe as an 
attempt to repair the damage. 
6.5 Characterization of lubricin (paper IV)  
The reduced expression of lubricin in human OA menisci and synovial fluid 
(Musumeci et al., 2014) is suggested to change the boundary-lubricating ability 
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of the articular cartilage surface, subsequently leading to the development of 
OA. Therefore, we wanted to investigate possible modifications in the levels of 
equine synovial lubricin and alterations in its glycosylation pattern from horses 
with OA. The O-linked glycosylation of lubricin is essential for the biological 
lubrication of the superficial zones of articular cartilage (Jay, 1992) but glyco-
epitopes on core 1 and 2 O-glycans also have the potential to interact with, for 
example selectins and galectins, to facilitate inflammation (Jin et al., 2012; 
Liaqat et al., 2012). Studies of human lubricin have shown that, in addition to 
the level of lubricin, both the glycosylation and its degradation products are 
potential markers for inflammation and disease progression of OA and RA 
(Liaqat et al., 2012). 
 Our results showed that the core 1 O glycans were the most dominating 
structure on equine lubricin, similar to the findings for human synovial fluid 
lubricin (Estrella et al., 2010). Additionally lubricin in synovial fluid from 
horses with structural OA lesions and joints with OCFs, had overall a reduced 
amount of sialylation of core 1 O-glycans compared to synovial fluid from 
normal joints. The removal of sialic acid and core 1 oligosaccharides has been 
shown to cause loss of boundary lubrication (Jay et al., 2001). 
Synovial fluid from normal joints contained a slightly elevated level of core 
2 O-glycans compared to synovial fluids from horses with OA or OCFs. This 
lack of complex core 2 O-glycan on lubricin may increase the susceptibility to 
endogenous proteolysis and decrease the carbohydrate-dependent interaction 
with other components in both cartilage and synovial fluid (Liaqat et al., 2012). 
Synovial lubricin from RA patients expresses core 2 O-glycans which 
comprise sialyl Lewis x, an epitope as well as sulfate substitution. Sialyl Lewis 
x is involved in binding to L-selectin ligands on polymorphonuclear 
granulocytes, indicating that lubricin also may be involved in 
polymorphonuclear granulocyte-mediated inflammation (Jin et al., 2012).  
However in our study, no fucosylated core 2 O-glycans were detected in any of 
the synovial fluid samples, indicating an absence of sialyl Lewis epitopes on 
equine synovial lubricin. 
Both quantitative proteomics and ELISA showed higher levels of lubricin in 
the medium from IL-1β stimulated explants. Western Blot analysis confirmed 
the high release of lubricin in this medium during the culturing period; 
however, medium from non-stimulated explants only showed immune 
detection at days 0-6 (Western Blot). IL-1β has been suggested to have 
multiple roles in controlling new synthesis of lubricin, as well as promoting 
degradation of the cartilage, and releasing lubricin into the media (Jones & 
Flannery, 2007). Other studies have found both N- and C-terminal fragments of 
lubricin in normal bovine synovial fluid (Schmidt et al., 2009; Rhee et al., 
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2005a), and in human OA synovial fluid samples (Kamphorst et al., 2007; 
Rhee et al., 2005a). 
We also identified peptides containing non-tryptic cleavage sites in 
synovial fluid from healthy and diseased joints and in media from stimulated 
and unstimulated explants. We detected a shared non-tryptic site at position 
LRPH|VLTP in lubricin from both the synovial samples and the media. This 
confirms the explant model as a suitable system for future studies on the role of 
inflammation in lubricin processing and decreased lubrication of the joints. 
 
6.6 Horse as a model system for translational OA research 
A recent population-based study in Sweden estimates that at least an additional 
26,000 individuals per 1 million in the population aged ≥45 years have 
consulted a doctor for OA in a peripheral (knee or hip) joint in year 2032 
compared to 2012 (Turkiewicz et al., 2014). Hence new tools for early 
diagnosis of OA with the aim of prevention and early treatment are warranted.  
There are many animal models of OA attempting to resemble the human 
disease. Genetically engineered mice studies have contributed valuable 
knowledge into the pathobiology of OA and identified disease-modifying 
targets (Little & Hunter, 2013). Another new approach for studying genomics 
of OA uses zebra fish (Mitchell et al., 2013) as a model; this animal model is 
suggested to be a link between in vitro cell or tissue cultures and in vivo studies 
with rodents (van der Kraan, 2013).  
The horse, as a model for OA, has many advantages; the prevalence of in 
vivo OA is high among racehorses and consequently there is a widespread 
knowledge in diagnosing clinical equine OA. The genome of the domestic 
horse shows a large synteny with the human genome, making the horse a 
suitable model for studying human diseases (Wade et al., 2009). Equine and 
human cartilage has similar geometrical and organizational structures with 
respect to cartilage thickness and GAG, DNA and collagen content (Malda et 
al., 2012). However it is much easier to obtain healthy equine articular 
cartilage for chondrocyte pellets or explant culturing than from human 
individuals. Moreover, results from the in vitro cultures of cartilage explants 
(paper III) showed a battery of ECM proteins paralleling some of those 
previously observed in human OA cartilage explants (Stenberg et al., 2013).  
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6.7 Change in diagnostic procedure of osteoarthritis  
Equine OA is clinically characterized by lameness including soft tissue 
swelling, and/or synovial effusion (McIlwraith et al., 2010). An increased 
degree of lameness is often seen after flexion of the joint. For lameness 
diagnosis of a specific joint, intra-articular anaesthesia in combination with 
flexion tests is used. The traditional diagnosis of OA relies heavily on imaging 
techniques such as radiographs, ultrasound, computed tomography and 
magnetic resonance imaging (MRI) to detect structural changes of the joint 
tissues. However the challenge for the future is to develop other diagnostic 
markers that could detect early molecular changes before irreversible joint 
damage. An assortment of cartilage-associated proteins is evaluated for this 
purpose. These molecular markers, also known as biomarkers, can be degraded 
proteins with specific catabolic epitopes, that preferably exists in OA joints, or 
anabolic neo-epitopes which correlate to synthesis/turnover of ECM molecules 
(Goldring & Goldring, 2007). The “OA biomarker consortium” study 
originated by the Foundation for the National Institute of Health is currently 
evaluating 12 different biomarkers in clinical studies of human knee and hip 
OA. The evaluations are based on ELISA assays and five of these markers are 
associated with collagen type II degradation while two are connected to bone 
resorption and the remaining ones with aggrecan turnover, cartilage 
degeneration, synovitis, type II collagen synthesis, and articular cartilage 
degradation (Hunter et al., 2014a). Suggested synovial fluid or serum 
biomarkers for early equine OA are CS846, CPII, Col CEQ (a marker of type 
II collagen degradation), C1, 2C, osteocalcin, Col I, and prostaglandin E2 
(Frisbie et al., 2008). The detection of degraded and/or new synthesis of 
COMP has been proposed as a marker of equine OA in several studies 
(Yamanokuchi et al., 2009; Arai et al., 2008; Arai et al., 2005; Skiöldebrand et 
al., 2001). There are positive correlations between synovial fluid levels of 
bone-specific alkaline phosphate and keratan sulphate with cartilage damage 
(Fuller et al., 2001). A suitable approach to identify new cleavage sites of 
candidate proteins is quantitative proteomics of articular cartilage (Peffers et 
al., 2014) and of the secretome (Peffers et al., 2013). The future goal of this 
research should be to achieve a biomarker panel based on unique protein 
fragments, representing different stages of OA. An optimal biomarker panel 
could be used in diagnosis, monitoring the progression of disease and in 
treatment evaluation.  
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7 Conclusions  
 
! Stimulation by IL-1β induces a catabolic response on ECM-related genes 
and proteins in chondrocyte pellets and cartilage explants in vitro, 
confirming IL-1β as a master cytokine in cartilage pathology.  
! IL-1β stimulation of cartilage explants leads to a release of ECM molecules 
at different time points with a final release of components of the collagen 
network.  
! HMGB-1 stimulation of chondrocyte pellets in vitro induces an 
upregulation of SOX-9, indicating a promotion of chondrocyte 
differentiation or increased metabolic state of chondrocytes. 
! Site-associated articular cartilage carpal deterioration is not explained by a 
topographically dependent altered response to cytokines in equine carpal 
OA.  
! IL-6 stimulation of chondrocyte pellets in vitro does not lead to a similar 
response as IL-1β; instead, IL-6 has a regulatory role in the inhibition of the 
canonical Wnt-signalling pathway, leading to a subsequent upregulation of 
GDF-5 mRNA gene expression. 
! GDF-5 protein is expressed in both normal articular equine cartilage and in 
OCFs, possibly indicating a repair attempt in the latter. 
! A change in O-glycosylation profile of lubricin is seen in synovial fluid 
from equine joints with OA/OCFs compared to synovial fluid from normal 
joints, with lower amounts of mono-sialylated core 1 O-glycans and higher 
amounts of di-sialylated core 1 O-glycans in the normal synovial fluid.  
! An endogenous proteolytic cleavage site of lubricin was found in vitro and 
in vivo. 
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8 Future research 
 
Basic research, delineating the pathological framework from the earliest 
molecular aspects of the disease until the late stage clinical OA, is important 
for future specific diagnostic techniques, drug development, and a correct 
prognostic evaluation. A new generation of biomarkers based on unique 
cleavage sites generated in the early stages of OA will give the opportunity to 
achieve early diagnosis of OA before joint destruction. Specific biomarkers 
could also be used in evaluating treatments and in assessing new training 
programs for the racehorse to prevent joint damage. 
 
To follow up the work with the in vitro models in this thesis, it would be of 
importance to: 
 
! Develop biomarker assays with the aid of the in vitro studies of 
cartilage explants (paper III) by producing monoclonal antibodies 
against specific neo-epitopes. These assays can then be used to 
detect specific cleavage sites of the ECM molecules in synovial 
fluid and serum from horses with different stages of OA. 
! Characterize the molecular changes in equine cartilage explants 
after IL-6 stimulation to further explore the possible regulatory 
effect of this cytokine.  
! Evaluate the effect of IL-6 on the secrection, glycosylation and 
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